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ABSTRACT 
 
A FGF-Hh Feedback Loop Controls Stem Cell Proliferation in the Developing Larval 
Brain of Drosophila melanogaster. 
(December 2007) 
Andrea Lynn Barrett, B.S., Sam Houston State University 
Chair of Advisory Committee:  Dr. Sumana Datta 
 
 
 The adult Drosophila central nervous system is produced by two phases of 
neurogenesis: the first phase occurs during embryonic development where the larval 
brain is formed and the second occurs during larval development to form the adult brain.  
Neurogenesis in both phases is caused by the activation of neural stem cell division and 
subsequent progenitor cell division and terminal differentiation.  Proper activation of 
neural stem cell division in the larval brain is essential for proper patterning and 
functionality of the adult central nervous system.  Initiation of neural stem cell 
proliferation requires signaling from the Fibroblast Growth Factor (FGF) homolog 
Branchless (Bnl) and by the Hedgehog (Hh) growth factor.  I have focused on the 
interactions between both of these signaling pathways with respect to post-embryonic 
neural stem cell proliferation using the Drosophila larval brain. 
 Using proliferation assays and quantitative real-time PCR, I have shown that Bnl 
and Hh signaling is inter-dependent in the 1st instar larval brain  and activates neural 
 iv 
stem cell proliferation.  I have also shown that overexpression of bnl can rescue 
signaling and neuroblast proliferation in a hh mutant.  However, overexpression of hh 
does not rescue signaling or neuroblast proliferation in a bnl mutant, suggesting that Bnl 
is the signaling output of the Bnl-Hh feedback loop and that all central brain and optic 
lobe neural stem cells require Bnl signaling to initiated proliferation. 
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CHAPTER I 
INTRODUCTION 
 
 For the proper development of any organism, genetic and morphological events 
must be spatially and temporally regulated.  The organism relies heavily on proper gene 
expression and function to coordinate cells that will eventually generate specific tissues 
and organs of the body.  After development, these same communication processes are 
needed for maintenance of areas by replacement/repair of cells in tissues or organs that 
no longer function properly due to injury or mortality.  However, strict regulation is 
needed to prevent aberrant cell growth, which could lead to loss of tissue/organ function 
or diseases such as cancer.  Therefore the study of fundamental signaling molecules and 
their downstream signaling pathways is paramount to understanding the processes 
undertaken during development, homeostasis, and repair of an organism.  The study of 
the regulation of stem cell proliferation in development is a key area of research where 
basic scientific knowledge gained using lower order model organisms can transcend the 
genomic complexity gap and significantly contribute to overall understanding of stem 
cell control. 
 Over the last few decades, the area of stem cell research has garnered a great deal 
of attention.  Many researchers believe that stem cells hold the key to regenerative 
medicine and cancer therapies.  Elucidating the mechanisms that regulate stem cell  
 
___________ 
This dissertation follows the style and format of Developmental Biology. 
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growth and differentiation into wanted cell types would revolutionize the medical 
community.  The potentials for the use of stem cell directed treatments of diseases like 
diabetes, Parkinson’s disease, and Rheumatoid Arthritis are high and growing 
exponentially. 
 In this dissertation, I examine the interactions between specific signaling 
molecules required for neural stem cell proliferation in Drosophila melanogaster and the 
significant contribution this study makes to overall understanding of stem cell 
proliferation control in the central nervous system. 
 
STEM CELLS 
Over the years, the definition of a stem cell has evolved to encompass specific 
defining features that include the capacity to self-renew and generate cell lineages that 
differentiate into a wide variety of cell types.  It is still not yet known how stem cells are 
controlled, how many different types there are, and where they are located in the body.  
There are three basic types of stem cells that make up the human body: germinal, 
embryonic, and adult stem cells (Bongso and Richards, 2004).  Germinal stem cells give 
rise to gametes in the human adult reproductive system, i.e. sperm and eggs.  Embryonic 
stem cells are the precursors of all human adult cells and are derived from the inner cell 
mass of an embryo in the blastocyst stage (Fallon et al., 2000; Stojkovic et al., 2004).  
Adult stem cells in humans are located in most tissues and are responsible for 
regenerating those tissues over time or upon injury (Lim et al., 2007; Serakinci and 
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Keith, 2006).  Each of these stem cell categories has varying potentials with regards to 
proliferation and plasticity/differentiation potential.  Stem cells divide in two fashions: 
symmetrically, where both daughter cells become stem cells or asymmetrically, where 
one of the daughter cells remains a stem cell and the other daughter begins the process of 
determination and adopts a different fate (Figure 1.1) (Maric et al., 2007).  The 
differentiation potential of stem cells can be broadly characterized as totipotent, 
pluripotent, or multipotent.  The only stem cells considered to be truly totipotent are the 
germ line stem cells which have the capacity to generate any cell in the body.  
Pluripotent stem cells are unable to generate all types of cells in the body but have the 
capacity to become most cells in the body.  Embryonic stem cells, the cells that make up 
the inner cell mass of the embryo at blastula stage, are considered to be pluripotent. The 
multipotent stem cell is more restricted in the types of cells it is able to generate but still 
retains the ability to generate several different types of cell.  Adult stem cells are for the 
most part considered multipotent stem cells (Serafini and Verfaillie, 2006; Shi et al., 
2007; Stojkovic et al., 2004). 
 
Adult stem cells 
Embryonic stem cells present an exciting avenue for cancer therapeutics and 
regenerative medicine, however they possess several issues, i.e. moral and 
immunological, that makes their use problematic.  Therefore, adult stem cells pose as an 
attractive alternative to embryonic stem cell research.  Adult stem cells were first  
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Figure 1.1.  Asymmetric stem cell division.  A stem cell divides asymmetrically 
generating two daughter cells.  One daughter cell is a new stem cell that replenishes the 
original pool of stem cells and the other daughter cell is a progenitor cell that has the 
potential to eventually generate any type of terminally differentiated cell in the body. 
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described in organs with high cell turnover, i.e. blood, skin, and gut (Metcalf, 1993).  
However, reports have shown that they can also be found in organs without high cell 
turnover like the central nervous system and heart.  Thus far, stem cells have been 
identified in many organs/tissues and include: hematopoietic stem cells (the best studied 
to date), neural stem cells, epidermal stem cells, skeletal muscle stem cells, and 
mesenchymal stem cells.   
 
Vertebrate neural stem cells 
 It was thought for some time that the adult brain was non-neurogenic and was 
completely formed at the end of embryogenesis.  However, it was quickly discovered 
that several areas of the vertebrate brain contain mitotically active cells.  These 
mitotically active cells were later determined to be neural stem/progenitor cells. To date 
the most well characterized areas are the subventricular zone (SVZ) of the lateral 
ventricle and the subgranular zone (SGZ) of the dentate gyrus within the hippocampus 
(Gage et al., 1995; Reynolds and Weiss, 1992; Vescovi et al., 1993).  Both areas contain 
a subpopulation of cells that are mitotically quiescent but have the capacity to proliferate 
asymmetrically to generate new progenitor cells that can migrate and differentiate into 
neuronal/glial cells upon the right stimulation.  Other areas of the vertebrate brain, like 
the cerebellum, striatum, tectum, and the neocortex all contain identifiable neural stem 
cells.  Interestingly, the spinal cord, originally thought to be strictly non-neurogenic, has 
recently been identified as a neurogenic region of the CNS, albeit at very low levels 
(Weiss et al., 1996).  
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 In the next chapter section, I will discuss in more detail the events that occur 
during vertebrate and insect neurogenesis and provide some insight into the potential 
mechanisms of stem cell generation and control. 
 
CENTRAL NERVOUS SYSTEM DEVELOPMENT 
 The central nervous system (CNS) is a very complex structure that is required for 
proper development of higher multicellular organisms and coordinates essential 
functions that include sensory mechanisms, movement, and cognition.  Therefore, study 
of the molecular and morphological components required for proper development and 
function of the central nervous system is an area that has been highly investigated.  In 
this chapter section, the development of the vertebrate central nervous system in Mus 
musculus and the insect central nervous system in Drosophila melanogaster will be 
addressed and a comparative analysis will be given. 
 
Vertebrate neurogenesis 
 The development of the vertebrate adult central nervous system occurs mostly 
during the development of the embryo with only a small fraction of neurogenesis 
occurring during adult life.  Neurogenesis begins in the embryo shortly after 
gastrulation, an early phase of embryogenesis where morphology of the embryo is 
dramatically restructured by cell migration. One of the first steps in neurogenesis occurs 
with induction of neural tube formation, a process called neurulation.  Along the dorsal 
surface of the embryo the prospective neuroectoderm is induced by the notochord, a 
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structure derived earlier from the mesoderm, to thicken and flatten into a structure called 
the neural plate.  The neural plate begins to invaginate at the midline of the neural tube.  
The neural plate will then begin to round up, detach from adjacent epidermal cells, and 
form the neural tube, which eventually gives rise to the adult brain and spinal cord 
(Arendt and Nubler-Jung, 1999; Ford-Perriss et al., 2001; Geldmacher-Voss et al., 
2003).   During these morphological changes, specification of the neuroectoderm is 
occurring through specific regional expression of proneural and neurogenic genes.  The 
neuroectoderm is subdivided into three columns on each side of the midline by the 
columnar genes nkx 2.2, genomic screen homeobox (gsh), and msx. Expression of these 
genes gives rise to the medial, intermediate, and lateral regions, respectively.  The 
medial region generates motoneurons and interneurons, while the intermediate region 
generates only interneurons.  The lateral region generates the neural crest where sensory 
neurons are located (Arendt and Nubler-Jung, 1999; Cornell and Ohlen, 2000).  In 
conjunction with the columnar genes, transcription factors encoded by the neurogenin 
and atonal genes establish proneural clusters.  Through a process called lateral 
inhibition, Delta-Notch signaling within the proneural cluster will induce differentiation 
and segregation of neural stem cells from the rest of the cells within the cluster (Arendt 
and Nubler-Jung, 1999). 
The neural tube is divided into three main layers.  The ventricular zone (VZ; 
adjacent to lumen of the neural tube), contains neural stem cells, called germinal cells, 
that divide asymmetrically giving rise to undifferentiated neuronal progeny that 
transiently populate the middle subventricular zone (SVZ).  The mantel layer/marginal 
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zone (MZ; adjacent to body cavity) contains differentiating neurons and axonal 
outgrowth.  Before neural tube closure, the CNS is subdivided along the anterior-
posterior axis into four distinct domains: forebrain, midbrain, hindbrain, and spinal cord.  
As neurogenesis progresses, a series of swellings and constrictions form as the wall of 
the neural tube grows at the fore-, mid-, and hindbrain regions, which give rise to the 
adult brain structure. Most cells in the brain and spinal cord continue to actively 
proliferate throughout embryogenesis but this is limited to the ventricular and 
subventricular zones (Arendt and Nubler-Jung, 1999; Cayuso and Marti, 2005; Dono, 
2003; Ford-Perriss et al., 2001).  
For many years it was thought that neurogenesis stopped after embryogenesis.  
However, this hypothesis was discarded when proliferating cells were identified in 
regions of the adult brain.  To date, neurogenic regions have been identified in two areas 
of the adult brain, the lateral ventricle and the dentate gyrus within the hippocampus 
(Cayuso and Marti, 2005; Temple and Alvarez-Buylla, 1999) (Figure 1.2).  Other areas 
in the brain including the neocortex, tectum, striatum, and even the spinal cord have also 
been shown to have post-natal proliferation, albeit at low levels (Cayuso and Marti, 
2005; Dahmane and Ruiz i Altaba, 1999; Dahmane et al., 2001; Dono, 2003; Palma et 
al., 2005; Stecca and Ruiz i Altaba, 2005; Temple and Alvarez-Buylla, 1999; von 
Bohlen Und Halbach, 2007).   A large amount of work has been published on the 
subventricular zone (SVZ) of the lateral ventricle and the subgranular zone (SGZ) of the 
dentate gyrus, both of which show sustained neurogenesis in the adult.  
 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2.  Areas of neurogenesis in the adult mouse brain.  A sagital view of the 
adult mouse brain with areas of neurogenesis labeled.  Two main areas of neurogenesis 
are the dentate gyrus (in green) of the hippocampus, shown in greater detail in box A, 
and the subventricular zone (SGZ) of the lateral ventricle (in blue), shown in greater 
detail in box B.  Other areas of neurogenesis, albeit at low levels, are the neocortex, 
striatum, Tectum, and cerebellum.  RMS, rostral migratory system utilized for migration 
of new neurons to the olfactory bulb from the SVZ. 
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The SVZ is the region of the adult brain that continually generates new neurons 
bound for the olfactory bulb and is composed of four basic types of cells: astrocytes, 
immature precursors, migrating neuroblasts, and ependymal cells (Doetsch et al., 1999; 
Temple, 1999). Through in vitro and in vivo studies, it has been shown that astrocytes 
are neural stem cells that divide asymmetrically to generate immature precursor cells.  
These precursor cells then give rise to neuroblasts that migrate along the rostral 
migratory system (RMS) to integrate into the olfactory bulb and differentiate into 
interneurons (Ahn and Joyner, 2005; Alvarez-Buylla et al., 2002). 
The SGZ is a region of the adult brain that generates new interneurons in the 
hippocampus, which is believed to play a role in memory.  Neurogenesis in the dentate 
gyrus is occurs in five stages.   First, neural progenitor cells begin to proliferate, which 
then allows transient amplifying cells to differentiate into immature neurons.  The 
immature neurons begin to migrate at short distance into the granule cell layer in the 
dentate gyrus, where it will send dendrites and axonal projections to establish synaptic 
contacts (von Bohlen Und Halbach, 2007).  Study of several neurogenic regions of the 
vertebrate brain have helped catapult the understanding of the mechanisms utilized in 
signaling to endogenous neural stem cells.   
 
Regulation of neural stem cell proliferation in vertebrate nervous system 
 Several signaling molecules have been shown to regulate the proliferation of 
neural stem cells in the vertebrate brain.  The signaling molecule, Sonic Hedgehog 
(Shh), is expressed by Pürkinje cells in the subventricular zone (SVZ).   In vitro 
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experiments which exogenous Shh is added to SVZ cultures cells show not only that Shh 
stimulates overall proliferation but also stimulates an increase in neural stem cell 
numbers and resulting neuron populations (Palma et al., 2005).  In contrast, when Shh 
signaling is hindered, SVZ cells proliferation decreases.  Currently, it was unclear which 
cells in the SVZ were the Shh receiving cells.  However, in vivo experiments where 
neural stem cells in the SVZ and SGZ were labeled at early post-natal time points and 
their responsiveness followed through long-term fate mapping.  Theses studies revealed 
that neural stem cells in both regions could respond to Shh signaling and can produce 
multiple lineages of cells for up to one year (Ahn and Joyner, 2005; Palma et al., 2005). 
 The ultimate goal in studying the mechanisms that control central nervous system 
development and regulation/maintenance is to be able to manipulate endogenous 
cells/tissue to either generate more of a specific cell/tissue for the purpose of 
regeneration or hinder the growth and propagation of disease/damaged tissue.  The 
mammalian vertebrate is a great model system for studying these processes.  However, 
the complexities inherent in a more evolutionarily sophisticated organism make 
dissecting the inner workings of these processes very difficult.  In the next chapter 
section, I will discuss neurogenesis events in Drosophila melanogaster that are similar to 
those seen in mammals.  My research shows that a less complex organism can answer 
the same basic mechanistic questions about regulation of post-embryonic neural stem 
cell proliferation. 
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Drosophila melanogaster neurogenesis 
The Drosophila model system is a very powerful experimental paradigm that is 
widely utilized.  The relatively small size (180 Mb) of the Drosophila genome reflects a 
smaller degree of genetic redundancy than is found in mammals.  For example, three 
FGF like molecules have been identified in Drosophila versus 22 in mammalian systems 
(Gryzik and Muller, 2004; Stathopoulos et al., 2004; Sutherland et al., 1996; Tsang and 
Dawid, 2004).The extensive knowledge of Drosophila biology, development, and the 
availability of numerous mutants make it an excellent system for the study of signaling 
pathways and their regulation of neural stem cell proliferation.  The relatively short life 
cycle, marked by distinct morphological stages, allows for quick and efficient 
experimental analysis. 
In comparing development of the central nervous system (CNS) of mammals and 
Drosophila, there are some obvious differences.  First, the vertebrate CNS develops on 
the dorsal side of the embryo while the CNS of Drosophila develops on the ventral side.  
Secondly, a neural tube does not develop in invertebrates.  Thirdly, the adult Drosophila 
CNS develops through two temporally regulated neurogenesis phases, embryonic and 
postembryonic.  During embryogenesis, generation of what will become the larval CNS 
occurs.  However, only approximately 10% of cells generated during embryogenesis will 
become apart of the adult CNS structure.  The other 90% is generated during larval and 
pupal stages (Maurange and Gould, 2005; Truman and Bate, 1988).  This is in contrast 
to development of the adult vertebrate CNS that is almost 100% established upon 
completion of embryogenesis. 
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However, there are many striking similarities between vertebrate and invertebrate 
CNS development.  During the Drosophila embryonic phase of neurogenesis, expression 
of vertebrate homologs of the columnar genes (i.e. ventral nervous system defective 
(vnd), intermediate neuroblast defective (ind), and muscle segment homeobox (msh)) 
working in concert with segment polarity genes (i.e. engrailed (en), wingless (wg), 
hedgehog (hh), and gooseberry-distal (gsb-d)) to divide the ventral and procephalic 
neuroectoderm into ‘neural equivalence groups’ (Figure 1.3A).  The neural equivalence 
group consists of five to seven neuroectodermal cells, of which only one will eventually 
adopt a neuroblast fate (Doe, 1992; Doe, 1996; Egger et al., 2007b; Urbach et al., 2003).  
The specification of a neuroblast from the equivalence group is first determined by the 
level of expression of the achaete-scute (ac/sc) complex, similar to neurogenin and 
atonal in mammals.  All cells in the equivalence groups express the ac/sc complex, 
however, the cell that expresses the highest level will begin to adopt a neuroblast fate 
(Egger et al., 2007b).  Neuroblast fate determination occurs through a process called 
lateral inhibition, where expression of the transmembrane ligand Delta by the 
presumptive neuroblast causes activation of the Notch receptor in adjacent cells.  The 
activation of the Notch signaling pathway down-regulates expression of proneural genes, 
effectively blocking those cells from adopting a neuroblast fate, and forcing them to 
adopt an epidermal fate (Figure 1.3C).  Morphological differentiation then occurs when 
the newly specified neuroblast enlarges and delaminates dorsally in the embryo.  After 
delamination, the neuroblast then begins to divide asymmetrically along the apico-basal 
axis in a stem cell-like fashion to generate two daughter cells, one being a new  
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Figure 1.3.  Steps of embryonic neurogenesis in Drosophila.  (A) Specification of the 
neuroectoderm by expression of ventral nervous system defective (vnd), intermediate 
neuroblast defective (ind), and muscle segment homeobox (msh) in columns parallel and 
bisymmetrical to the midline along with expression of other genes generates “neural 
equivalence groups” in a repeated segmental pattern.  (B) Formation of the neuroblast 
occurs when the presumptive neuroblast cell begins to delaminate from the 
neuroectoderm in the basal direction and begins asymmetric division to generate a 
progenitor cell that will give rise to two neurons/glia.  (C) Schematic of lateral inhibition 
between a presumptive neuroblast and a presumptive epidermal cell.  Where the 
neuroblast expresses delta at a higher level than the epidermal cell, therefore activating 
the Notch receptor causing an inhibition of proneural gene expression.  This process 
effectively tells the presumptive epidermal cell to not because a neuroblast and adopt the 
epidermal cell fate. 
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neuroblast and the other a ganglion mother cell (GMC) (Figure 1.3B).  The GMC will 
then divide symmetrically to generate two progenitor cells that will differentiate into 
neurons and/or glial cells (Doe, 1996; Hartenstein et al., 1987; Prokop and Technau, 
1991).  This will generate the central brain (CB), thoracic (Th), and abdominal (Ab) 
neuroblasts of the CNS.  The optic lobe region of the brain, which generates the optic 
lobe (OL) neuroblasts, derives from an embryonic optic placode that is located 
dorsolaterally behind the developing brain.  Not until all of the neuroblasts in the rest of 
the CNS are formed (embryonic stage 11) does the optic placode invaginate and fuse to 
the basal surface of the brain hemisphere (Ebens et al., 1993; Egger et al., 2007a; Green 
et al., 1993; Hartenstein, 1993).  All neuroblasts continue to asymmetrically divide, 
except for the OL neuroblasts, which divide symmetrically, throughout embryogenesis 
to generate the larval nervous system.  However, in late embryogenesis all but ten 
neuroblasts, the mushroom body (MB) and ventral lateral (VL) neuroblasts, enter into a 
state of quiescence until later larval stages (Prokop and Technau, 1991; Truman and 
Bate, 1988). 
 The postembryonic phase of neurogenesis begin during the 1st instar larval stage 
and ends during pupal stage (Ito and Hotta, 1991).  For the formation of the adult CNS, 
resurrection of neuroblast proliferation and asymmetric division is needed to generate 
the bulk of neuronal cells that encompass the CNS.  The reactivation of neuroblast 
proliferation occurs in a distinct temporal and spatial pattern (Figure 1.4).   The first 
subpopulation of neuroblasts to exit a state of quiescence and begin proliferation and 
asymmetric division in a stem cell like fashion are the CB neuroblasts during the late 1st  
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Figure 1.4. Post-embryonic neuroblast proliferation is spatially and temporally 
regulated. Neuroblasts in the larva can be subdivided into 3 main groups based on their 
temporal reactivation of proliferation.  The mushroom body (MB) and ventral lateral 
(VL) neuroblasts (in pink) remain proliferative throughout embryonic and larval life.  
The optic lobe (OL) and central brain (CB) neuroblasts (in blue) exit quiescence at mid 
1st instar.  The thoracic (Th) neuroblasts (in green) exit quiescence at early 2nd instar. 
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instar larval stage. The next subpopulation of neuroblasts to enter into a proliferative 
state is the OL neuroblasts.  The last subpopulation to exit quiescence are the thoracic 
neuroblasts, which begin division during the early 2nd instar larval stage.  Most of the 
research done in neural development of Drosophila involved investigating neuroblast 
formation and identification in the ventral and procephalic neuroectoderm region of the 
CNS.  Therefore, little information is known about OL neuroblast formation.  It has been 
reported that the cells in the optic lobe are neuroblasts that divide symmetrically, then 
later switch to asymmetric division during late 2nd instar.  These neuroblasts separate 
into the inner proliferative center (IPC) and outer proliferative center (OPC) which 
develops into structures of the adult visual system (Ebens et al., 1993; Egger et al., 
2007a; Hofbauer and Campos-Ortega, 1990).  However, recently it was shown that the 
symmetrically dividing cells are neuroepithelial cells that eventually give rise to 
neuroblasts that will divide asymmetrically (Egger et al., 2007a).  The transition from a 
quiescent to dividing neuroblast in the unique Drosophila larval CNS results in an 
attractive model to study regulation of neural stem cells. 
 
Regulation of Neuroblast proliferation in Drosophila melanogaster 
 Multiple genes have been shown to regulate the re-activation of neuroblast 
proliferation in the larval CNS, most through the control of the G1-S transition of the 
cell cycle (Figure 1.5).  terribly reduced optic lobes (trol) is a gene that was initially 
identified in a screen for abnormal morphology of the larval brain lobe and encodes the 
Drosophila Perlecan, a heparan sulfate proteoglycan  
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Figure 1.5.  Genes shown to genetically interact in regulation of neuroblast 
proliferation during larval neurogenesis in Drosophila. 
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(Datta and Kankel, 1992; Voigt et al., 2002).  In trol loss-of-function mutants, 
reactivation of neuroblast proliferation is severely hindered.  Proliferation of the OL, 
CB, and most notably the Th neuroblasts are affected (Datta, 1995).  The neuroblast 
proliferation defect can be rescued by ectopic expression of cyclin E, not cyclin B, 
suggesting that the neuroblasts are arrested in the G1 phase of the cell cycle.  Over 
expression of string (stg), which encodes Drosophila Cdc25, also rescues the neuroblast 
proliferation defect in trol loss-of-function mutants, strengthening the argument that the 
neuroblast are G1 arrested (Caldwell and Datta, 1998; Park et al., 2003a).  In contrast, 
anachronism (ana) loss-of-function mutants show an increase in neuroblast reactivation. 
This suggests that ana, which encodes a glycoprotein that is secreted from neighboring 
glial cells, is required for maintenance of quiescence (Ebens et al., 1993).  Analysis of 
the trol/ana double mutant shows ana as epistatic to trol; suggesting that Trol is most 
likely required to repress Ana function or bypass its repressive effect on the cell cycle 
(Datta, 1995). 
 It has been widely discussed that components of the extracellular matrix of a cell 
can interact with other external signaling molecules (i.e. growth factors, receptors).  Two 
genes, hedgehog (hh) and branchless (bnl), have been shown the genetically enhance the 
neuroblast proliferation phenotype in a trol mutant background.  Through co-
immunoprecipitaton studies, it was shown that FGF-2 (human homolog of Branchless) 
and Hh physically interact with Trol (Park et al., 2003b).  This suggests that Hh and Bnl 
regulate the onset of neuroblast proliferation and their signal is mediated through Trol.   
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In this section I have given a thorough analysis of development of the central 
nervous system in both vertebrates and invertebrates.  I have discussed the similarities in 
gene function with regards to regulation of neural stem cell proliferation.  I am interested 
in gaining a better grasp of the mechanism/s utilized by these signaling molecules in 
regulating neural stem cell proliferation in Drosophila.  More specifically, I am 
interested in understanding the interaction between the Hedgehog and Branchless 
signaling pathways and how together, they regulate neural stem cell division. 
 
FIBROBLAST GROWTH FACTOR SIGNALING PATHWAY 
The development and complex patterning of the embryo is specified and 
regulated by a host of different signaling factors.  The fibroblast growth factor (FGF) 
signaling pathway is one of the major signaling pathways that have been shown to be 
key to several processes during embryonic development.  The different processes range 
from mesoderm induction and tracheal development to limb formation and neural 
development.  The FGF signaling pathway has also been implicated in post embryonic 
homeostasis, i.e. wound healing, angiogenesis, tumor development and progression 
(Bottcher and Niehrs, 2005; Powers et al., 2000; Sutherland et al., 1996; Venkataraman 
et al., 1999).   
The FGF ligand is a member of a large family of polypeptide growth factors that 
have been identified in organisms from nematodes to humans (Ornitz and Itoh, 2001; 
Thisse and Thisse, 2005).  The first FGF molecule, FGF-2 (basic FGF), was identified 
by Hugo Armelin in 1973 as a mitogen that could stimulate growth in mouse NIH3T3 
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fibroblasts.  To date, 22 FGF family members (FGF1-23) have been identified in mouse 
and humans.  They range from 17 to 34 kDa in molecular weight and share 13-71% 
amino acid identity.  Only three FGFs, Branchless (Bnl), Pyramus (Pyr), and Thisbe 
(Ths), have been identified in Drosophila and are considerably higher in molecular 
weight, i.e. ~80kDa (Bottcher and Niehrs, 2005; Groth and Lardelli, 2002; Gryzik and 
Muller, 2004; Ornitz, 2000; Ornitz and Itoh, 2001; Stathopoulos et al., 2004; Sutherland 
et al., 1996; Thisse and Thisse, 2005).  The general FGF protein structure has four 
domains that include a signal peptide, an amino-terminus, a 120 amino acid highly 
conserved core region, and a carboxy-terminus (Figure 1.6A). The core region has been 
shown to be the region for binding to the fibroblast growth factor receptor (FGFR) and 
heparan sulfate proteoglycans (HSPGs), which are required for receptor activation (Kan 
et al., 1993; Ornitz, 2000; Venkataraman et al., 1999).   
The FGF receptor is a transmembrane protein that is a member of the receptor 
tyrosine kinase superfamily (RTK) and is structurally composed of three Ig domains, a 
heparan-binding domain, and a tyrosine kinase domain (Figure 1.6B). The vertebrate 
FGFs signal through one of four FGF receptors, whereas Drosophila FGFs signal 
through one of only two FGF receptors, i.e. Breathless (Btl) and Heartless (Htl).  
Activation of the FGF receptor induces signaling through several pathways, which 
include the phospholipase C gamma (PLC-γ) pathway, phosphatidylinositol-3 kinase 
(PI3K)/AKT pathway, and the main signaling cascade, the Ras/mitogen activated protein 
kinase (Ras/MAP kinase) pathway (Bottcher and Niehrs, 2005; Sutherland et al., 1996; 
Tsang and Dawid, 2004) (Figure 1.7).  The PLC-γ pathway involves PLC-γ binding to a  
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Figure 1.6.  Domain structures of FGF and the FGF Receptor.  (A) FGF contains 4 
main domains: signal peptide, amino-terminal domain, core domain for FGFR and 
heparan sulfate proteoglycan (HSPG) binding, and a carboxy-terminal domain.  (B) The 
FGF Receptor contains 3 Ig domains, alternative splicing of the 3rd Ig domain gives 
receptor specificity to different FGFs.  The acidic box binds bivalent cations and is 
required for optimal HSPG binding.  The heparin-binding domain interacts with the 
extracellular matrix (ECM).  The transmembrane domain maintains conformation for 
ligand dependent activation.  The juxtamembrane domain is required for binding to 
FRS2.  Both kinase domains are the catalytically active portion of the receptor and bind 
adaptor proteins when activated (Bottcher and Niehrs, 2005). 
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Figure 1.7.  The Fibroblast Growth Factor signaling pathway.  Activation of 3 
signaling pathways can occur upon receptor activation.  The RAS/MAP Kinase pathway 
(in green) is main signaling pathway.  The other two signaling pathways are the PI3 
Kinase/AKT pathway (in blue) and the PLCγ/Ca2+ pathway (in red). 
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phosphorylated tyrosine on the FGF receptor, where activation causes hydrolysis of 
phosphoatidylinositol-4,5-diphosphate (PIP2) into inositol-1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG).  IP3 and DAG activate protein kinase C (PKC) and release of 
Ca2+, respectively, which has been implicated in axonal growth in vertebrates.  The 
PI3K/AKT pathway can be activated by several methods, which involve two 
components of the Ras/MAP Kinase pathway, Grb2 and Ras, which phosphorylates the 
p85 or p110 subunits of PI3K, respectively.  The other method is FGF receptor 
activation of the p85 subunit.  This pathway has been shown to work parallel to the 
Ras/MAP kinase pathway in mesoderm induction (Bottcher and Niehrs, 2005).  The 
Ras/MAP kinase pathway involves binding and phosphorylation of FGF receptor 
substrate 2 (FRS2), which recruits the adaptor protein growth factor receptor-bound 
protein-2 (Grb2) and forms a complex with Son of sevenless (SOS), a guanine 
nucleotide exchange factor.  SOS then activates Ras by GTP exchange and initiates the 
MAP kinase signaling cascade (Bottcher and Niehrs, 2005; Groth and Lardelli, 2002; 
Tsang and Dawid, 2004). 
 
HEDGEHOG SIGNALING PATHWAY 
 The Hedgehog (Hh) signaling pathway is an essential signaling pathway 
involved in cell growth, tissue patterning, and cell differentiation during embryonic 
development.  The Hedgehog pathway retains its signaling capacity throughout adult life 
and in addition to developmental roles been shown to be involved in tissue homeostasis.  
More recently, the misregulation of Hedgehog signaling has been implicated in a variety 
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of cancers, including basal cell carcinomas (BCC), medulloblastoma, prostate cancer 
(PCa), pancreatic cancer, small-cell lung cancer, and breast cancer (Kubo et al., 2004; 
Lau et al., 2006; Oliver et al., 2005; Shaw and Bushman, 2007; Thayer et al., 2003; 
Watkins et al., 2003).  
The hedgehog (hh) gene was first discovered in Drosophila in a classic genetic 
screen looking for defects in segmental patterning (Nusslein-Volhard and Wieschaus, 
1980).  The Drosophila hh gene encodes for a ~ 46 kDa full-length precursor protein that 
undergoes posttranslational modifications.  First, the C-terminal end of the protein is 
responsible for autoproteolytic cleavage of the precursor protein into two biochemically 
distinct products, a  ~19 kDa segment called HhN (for N-terminal portion) and a ~ 25 
kDa segment called HhC (for C-terminal portion) (Lee et al., 1994; Porter et al., 1995). 
The HhN product, responsible for all biological function, is further modified by addition 
of a cholesterol moiety during the autocatalytic event.  Lastly, addition of a palmitate 
fatty acid group is achieved by action of an o-acyl transferase encoded by the 
rasp/skinny hedgehog (ski)/sightless (sit) gene in the Golgi complex before secretion (Ho 
and Scott, 2002; Ingham and McMahon, 2001; Micchelli et al., 2002; Miura and 
Treisman, 2006; Porter et al., 1996).  The modified HhN product is then called HhNp 
(for processed).  HhNp is then secreted from the producing cell by action of a 12 pass-
transmembrane protein with a sterol-sensing domain (SSD) called Dispatched.  
Dispatched is only required in the Hh sending cell and requires the cholesterol moiety on 
Hh for proper function (Burke et al., 1999).  There have been four vertebrate homologs 
of Hedgehog identified: Tiggywinkle Hedgehog (Twhh), Desert Hedgehog (Dhh), Indian 
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Hedgehog (Ihh), and Sonic Hedgehog (Shh) which are also posttranslationally processed 
in the same fashion (Ingham and McMahon, 2001; Pepinsky et al., 1998).  
Upon secretion, the Hh ligand participates in short- and long-range signaling.  
The presence of the cholesterol and palmityl groups, regulates the range of signaling 
through membrane tethering, multimerization, and trafficking by extracellular protein 
interactions (Gallet et al., 2003; Lum and Beachy, 2004; Zeng et al., 2001).  Hh 
signaling is mediated through Patched receptor binding.  Patched (Ptc) is a 12 pass-
transmembrane protein that contains a sterol-sensing domain (SSD) similar to 
Dispatched (Taipale et al., 2002).  In the absence of Hh binding, Ptc acts as a repressor, 
inhibiting the function of another 7 pass-transmembrane protein, called Smoothened 
(Smo).  This repression allows phosphorylation of the transcription factor Cubitus 
Interruptus (Ci) by cAMP dependent protein kinase A (PKA) and formation of a 
cytoplasmic protein complex bound to microtubules, composed of Costal-2 (Cos2), 
Fused (Fu), Suppressor of Fused (Su(Fu)), and Ci.  While in this protein complex, Ci is 
targeted for partial degradation by an E3-ubiquitin ligase, called Slimb in Drosophila.  
The portion of Ci that is remaining, termed CiR, translocates to the nucleus, where it acts 
as a repressor of target gene expression.  However, in the presence of ligand, Hh binds to 
the Ptc receptor, relieving repression of Smo function.  The Cos2/Fu/Ci/Su(Fu) protein 
complex is dissociated by recruitment of Cos2 and Fu to the a cytoplasmic domain of 
Smo.  This effectively bypasses of Ci proteosomal degradation, which in turn allows for 
an active form of Ci, termed CiA, to enter the nucleus and turn on expression of specific 
hh target genes, like ptc (Figure 1.8).  In vertebrates, there have  
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Figure 1.8.  The Hedgehog signaling pathway.  Without Hh activation, the Hh receptor 
Patched represses the action of Smoothened.  This allows for the binding of Ci to the 
Su(Fu)/Cos2/Fu complex allowing Slimb and PKA to cleave Ci into a repressive form, 
CiR, that enters the nucleus and blocks transcription of Hh target genes.  With Hh 
activation, Patched repression is removed allowing Smoothened to interact with Fu.  
This prevents Ci from binding to the Su(Fu)/Cos2/Fu complex, therefore allowing Ci to 
enter the nucleus in an activator form, CiA. 
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been two patched and one smoothened gene identified, patched1, patched2 and 
smoothened.  There have also been three ci family genes identified, called gli1, gli2, and 
gli3, which exhibit a more complex activator/repressor paradigm than Ci processing in 
Drosophila (Ingham and McMahon, 2001; Jia and Jiang, 2006; Lum and Beachy, 2004; 
Lum et al., 2003; Nybakken and Perrimon, 2002). 
 
FIBROBLAST GROWTH FACTOR AND HEDGEHOG SIGNALING 
INTERACTIONS 
 Signaling pathways and their roles in development through regulation of cell 
proliferation, differentiation, survival, and maintenance is a very widely studied area. 
There are arguably only five main signaling pathways utilized during development of the 
embryo: the Hedgehog (Hh), Wingless (Wnt), Fibroblast Growth Factor (FGF), 
Delta/Notch, and Bone Morphogenetic Protein (Bmp) signaling pathways.  In studying 
these signaling pathways, it has become evident that many processes of development 
require multiple signaling cascades for proper induction, growth, and patterning.  
Therefore, elucidation of interactions between signaling pathways, is key to understand 
the complexities of developmental regulation.  In this section, I will discuss more 
specifically about how the FGF and the Hh signaling pathways interact, i.e. dependently 
or independently, in multiple areas of development. 
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FGF and Hh dependent signaling 
 Within the past few decades the study of both the FGF and Hh signaling 
pathways have greatly advanced.  The first studies of Hh showed that it was required for 
proper segmental patterning in Drosophila embryos (Nusslein-Volhard and Wieschaus, 
1980).  Since that time, the number of developmental and non-developmental process es 
attributed to Hh continues to grow everyday.   
Due to cellular diversity generated in a multicellular organism, is not hard to 
imagine that differing interactions between two signaling pathways in different areas of 
development would be seen.  For example, one of the first interactions established 
between the Hh and FGF signaling pathways is the positive feedback loop generated 
during vertebrate limb bud growth and patterning.  After induction of the mesenchymal 
cascade, i.e. expression of the Gremlin and Formin genes by some unknown mechanism, 
FGF4 is activated by Gremlin in the apical ectodermal ridge (AER). FGF4 is required 
for maintenance of Sonic hedgehog (Shh) expression in the posterior limb bud 
mesoderm called the zone of polarizing activity (ZPA), which is considered to be a 
signaling center essential for limb patterning.  Shh is in turn required for maintenance 
and propagation of Formin and Gremlin expression in the ZPA, effectively closing the 
positive feedback loop (Laufer et al., 1994; Nissim et al., 2006; Niswander et al., 1994; 
Zuniga et al., 1999). This example shows that maintenance of Shh and fgf expression is 
dependent on activity of the opposite signaling pathway.  An important factor in this 
positive feedback loop is that there are intermediate players that mediate the loop. 
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 Shh and FGF signaling through a positive feedback loop is also shown to occur 
in proliferation induction of stem/progenitor cells of the ciliary body/ ciliary marginal 
zone (CB/CMZ) of the embryonic chick retina, therefore inducing retinal regeneration if 
the retina is injured or removed. This particular example shows a more direct interaction 
of both signaling pathways.  If the FGF pathway is inhibited, regeneration stimulated by 
Shh is also inhibited.  The opposite is also true: if the Shh pathway is inhibited, 
regeneration stimulated by FGF is inhibited.  Elucidation of this interaction is taken 
further by detecting that both FGF and Shh induce Erk phosphorylation, a component of 
the RAS/MAP Kinase cascade generally employed by FGF signaling.  Shh signaling was 
also determined to up-regulate expression of several members of the FGF signaling 
pathway (Spence et al., 2007; Spence et al., 2004).  These models for FGF and Hh 
signaling in two very different areas of the body show that pathway inter-dependence 
can occur in a variety of fashions to elicit the same outcome. 
 
FGF and Hh independent signaling 
 During development of the vertebrate central nervous system, the FGF and Shh 
signaling pathways are utilized extensively, as evidenced by expression patterns of both 
growth factor and growth factor receptor.  In the developing spinal cord, 
oligodendrocytes originate from the ventral neural tube at restricted foci.  This is 
influenced by Shh secreted from the notochord and floorplate of the neural tube. Shh 
induces expression of Olig1 and Olig2, basic helix-loop-helix transcription factors 
(Chandran et al., 2003).  Therefore, you would expect isolated neural stem cells from 
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this region of the spinal cord to be Shh responsive in formation of oligodendrocytes.  
However, isolated neural stem cells were shown to respond to FGF2 signaling by 
forming oligodendrocyte cells.  In addition they expressed Olig2 without stimulation by 
Hh.  Based on these results, Chandran et al hypothesized that FGF2 induced 
oligodendrocyte formation by stimulating the Shh pathway.  To test this, they added 
cyclopamine, an inhibitor of Hh signaling, to the FGF2 responsive neurosphere culture 
and assayed for oligodendrocyte formation.  In addition, they also isolated FGF2 
responsive neural stem cells from Shh null mice and assayed for oligodendrocyte 
formation.  In both cases, oligodendrocyte formation was seen, suggesting that in vivo 
Shh influenced neural stem cells are stimulated in vitro by FGF2 through a Shh 
independent pathway (Chandran et al., 2003). 
 Independent signaling of FGF and Shh is also seen in the development of the 
ventral telencephalon of the vertebrate forebrain.  It was known that Shh is expressed in 
the notochord and ventral area of the neural tube, including the forebrain, and is required 
for proper development of ventral cell types.  When Shh is lost, a ventralizing defect is 
seen.  However, loss of the Shh gene and the Shh pathway repressor gene Gli3 has little 
effect on the development of the ventral structure of the brain (Gutin et al., 2006).  It was 
thought that another player must be involved in ventralization of the CNS.  Because 
FGFs and FGFRs are known to be extensively expressed throughout the developing 
vertebrate brain, it was thought that they may be involved in ventral development of the 
brain.  This was shown to be the case because loss of Fgfr1 or Fgfr3 in the telencephalon 
caused loss of ventral differentiated cells (Gutin et al., 2006). Loss of both Fgfr1 and 
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Fgfr2, mimicked the phenotype of Shh loss.  However, expression of Shh and Gli1 are 
not affected, indicating no Fgfr dependence in the ventral brain.  Surprisingly, loss of 
Gli3 does not rescue the dorsalized phenotype that was seen in the Shh mutant (Gutin et 
al., 2006).  This suggests that both Fgfr and Shh are required for development of the 
same areas in the ventral region of the vertebrate brain but that the two signaling 
pathways are independent of one another (Gutin et al., 2006). 
 Hh and FGF signaling pathway interactions have been extensively studied in 
many areas of development.  However, not much is known about the interactions of 
these two pathways and neural stem cell proliferation.  My dissertation proposes to fill 
this gap by determining the molecular mechanism of Hh-FGF interaction in the 
activation of stem cell division in the Drosophila central nervous system. 
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CHAPTER II 
BRANCHLESS AND HEDGEHOG OPERATE IN A POSITIVE 
FEEDBACK LOOP TO REGULATE THE INITIATION OF 
NEUROBLAST DIVISION IN THE Drosophila LARVAL BRAIN 
 
INTRODUCTION 
The proper coordination of proliferation and patterning in developing organisms 
requires the interaction of different signaling systems.  Two of these systems, the 
RAS/MAPK pathway activated by fibroblast growth factor (FGF) and the Hedgehog 
(HH) pathway, are frequently paired during critical stages of organogenesis.  For 
example, classical developmental paradigms such as limb formation (Campbell, 2002; 
Martin, 1998; Nissim et al., 2006) and central nervous system patterning (Bertrand and 
Dahmane, 2006; Park et al., 2003b) require the coordinated actions of both RAS/MAPK 
and HHs in vertebrates and invertebrates alike.   Closer examination of the interplay 
between the FGF and HH pathways in disparate developmental systems, however, 
reveals many different mechanisms through which these two pathways interact to 
regulate developmental events. 
The first possibility is that HH and FGF/MAPK signaling operate as two 
independent pathways.  For example, in the mouse ventral telencephalon, FGF signaling 
is independent of Sonic Hedgehog (SHH) and does not affect expression of either SHH 
itself or its target gene and effector GLI1 (Gutin et al., 2006).   Furthermore, loss of the 
SHH target and transcription repressor GLI3 does not rescue the FGFR1; FGFR2 
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phenotype.  Here FGF appears to act later than, but independently of, SHH.  Both FGF 
and SHH can stimulate the production of oligodendrocyte precursors from neural stem 
cells.  Blockage of SHH signaling by addition of cyclopamine or by use of SHH-null 
stem cells has no effect on FGF2-based oligodendrocyte generation, indicating that the 
FGF signaling is not dependent on SHH ligand (Chandran et al., 2003) although this 
does not eliminate the potential for interaction based on intracellular signaling 
components.   
A second possibility is that HH signaling inhibits expression of FGF.  This 
phenomenon has been observed during budding morphogenesis in the mouse lung.  SHH 
is expressed in the tips of the distal epithelium in day 11.5 embryonic lung buds 
(Bellusci et al., 1997; Bellusci et al., 1996).  Application of exogenous SHH down-
regulates the expression of FGF10 while culture of the same cells without SHH results 
in an up-regulation of FGF10 (Lebeche et al., 1999).  Furthermore, in SHH knockout 
mice, FGF10 shows widespread expression compared to controls (Pepicelli et al., 1998).  
Analysis of FGF10 expression in HIP1 knock-out mice showed that loss of the SHH 
inhibitor HIP1 results in up-regulation of SHH signaling and almost complete repression 
of FGF10 expression with a resultant loss of secondary branching morphology (Chuang 
et al., 2003).  It should be noted that not all FGFs are down regulated by SHH - the same 
culture paradigm that resulted in inhibition of FGF10 expression produced up-regulation 
of FGF7 (Lebeche et al., 1999), demonstrating that the interaction between SHH and 
FGFs is FGF specific.  Up-regulation of FGF by HH signaling has been observed in 
several systems including the eye and brain.  In the Xenopus eye, expression of Banded 
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Hedgehog increases expression of FGF8 (Lupo et al., 2005).  In the zebrafish forebrain, 
inhibition of Hh signaling decreases expression of FGF3, FGF8 and FGF19 (Miyake et 
al., 2005).  In this case, FGF19 appears to act downstream of HH signaling since over-
expression of FGF19 can at least partially rescue the effects of HH inhibition.  
Hedgehog also regulates FGF expression in the zebrafish mid/hindbrain (Blaess et al., 
2006).  When SHH signaling is inhibited by conditional knockout of the pathway 
component Smoothened, FGF8 expression is severely reduced and expression of the Hh 
target and transcription repressor GLI3 increases.  This is in agreement with the 
observation that the FGF8 expression domain increases in size in GLI3 mutant mice 
(Aoto et al., 2002), and suggests that FGF8 expression is maintained by inhibition of 
GLI3 activity due to SHH signaling. 
Conversely, HH expression may require FGF signaling. For example, in the 
zebrafish forebrain, inhibition of both FGF3 and FGF8 expression resulted in a down-
regulation of SHH (Walshe and Mason, 2003).  Alternatively, the HH and FGF pathways 
can integrate at the level of intracellular components.  FGF has been shown to induce 
expression of GLI2, a transcription factor and HH signaling effector in ventroposterior 
development in zebrafish (Brewster et al., 2000).  In chick, ectopic application of SHH 
results in retinal regeneration, and addition of an FGFR antagonist blocks SHH-mediated 
regeneration (Spence et al., 2004).  Similarly, addition of an FGFR antagonist to cultured 
mouse neocortical precursors inhibits SHH-mediated generation of oligodendrocyte 
precursors (Kessaris et al., 2004).  Furthermore, inhibition of the MAPK pathway also 
blocked SHH-mediated events.  Addition of SHH does not detectably activate MAPK, 
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suggesting that low endogenous levels of MAPK activation are sufficient for SHH 
signaling.  The requirement for MAPK activation in SHH signaling has also been 
observed in NIH 3T3 cells (Riobo et al., 2006).  Of course the classic example of FGF 
and SHH interplay is the development of the chick limb bud (Martin, 1998).  In this 
system, several FGFs set up a signaling center at the tip of the bud that turns on 
expression of SHH in the posterior limb mesenchyme.  In turn, SHH signaling is 
required for maintenance of FGF4, FGF9 and FGF17 expression in the bud tip.  This 
function of SHH occurs through the expression of Gremlin, an inhibitor of Bone 
Morphogenetic Protein signaling (Zuniga et al., 1999).  Gremlin inhibition of Bone 
Morphogenetic Protein signaling prevents down-regulation of the FGFs.  Thus a positive 
feedback loop exists between SHH and FGFs, mediated by Gremlin.  FGF and HH 
signaling are also critical to initiate the proliferation of neural stem cells, or neuroblasts, 
in the Drosophila larval brain (Park et al., 2003b).  In this system, Branchless (Bnl, a 
Drosophila FGF homolog) and Hh signaling are modulated by the proteoglycan Trol 
(the Drosophila Perlecan homolog).  Decreased signaling by either Bnl or Hh results in 
fewer neuroblasts beginning cell division at late 1st instar.  However, whether this is due 
to independent parallel pathways that target different subsets of neuroblasts or 
interaction between the two pathways to control neuroblast division is not yet known.  In 
this study we have found evidence of a positive feedback loop between Hh and Bnl 
signaling in the larval brain.  We demonstrate that hh expression and signaling depend 
on Bnl activity, and vice versa.  Both hh and bnl expression are present in the larval 
brain lobes upon hatching, as are expression of the Hh and Bnl response genes patched 
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(ptc) and pointed (pnt), respectively.  Use of the temperature-sensitive hh allele hhts2 
demonstrated that the Hh Bnl feedback loop is initiated during embryogenesis.  Finally, 
epistatic and double mutant studies also support a positive feedback loop model with Bnl 
signaling as the output of the pathway that activates the division of all mitotically 
arrested neuroblasts in the brain lobe. 
 
MATERIALS AND METHODS 
Genetic strains and transgenes 
Flies were grown in standard medium at 25°C, unless otherwise stated.  Markers 
and balancer chromosomes are described in flybase.  Due to the variability of genetic 
background and their effects on neuroblast division and gene expression, crosses were 
designed such that sibling controls could be used in all studies. 
 
BrdU incorporation and neuroblast counting 
5-bromodeoxyuridine (BrdU) incorporation was preformed by placing 1st instar 
larvae on Kankel/White medium containing 0.1mg/ml BrdU from 16-20 hours post 
hatching (hph).  The larvae were then dissected, fixed, and labeled.  BrdU visualization 
was observed with a primary mouse anti-BrdU antibody 1:100 dilution (BD-
Biosciences) and a goat anti-mouse horseradish peroxidase secondary 1:200 dilution 
(Jackson ImmunoResearch).  Signaling was developed using diaminobenzidine (DAB) 
and mounted in PBST for visualizing on a Zeiss axiophot compound microscope.  
Neuroblast counting was preformed by visual examination.  Proliferating neuroblasts 
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were identified by morphology of their nucleus when labeled with BrdU. 
 
Developmental staging 
Larvae were developmentally synchronized by collecting newly hatched 1st instar 
larvae in one-hour windows.  
 
RNA isolation and Real Time PCR 
For RNA isolation, total RNA was extracted using Trizol Reagent (Invitrogen) 
according to manufacturer’s protocol.  For qRT-PCR, total RNA was DNase 
(Invitrogen) treated and reverse transcribed with SuperScript First Strand RT-PCR kit 
(Invitrogen) using oligo(dT) primers. SYBR Green (Applied Biosystems) was used to 
run the reactions on a BioRad iCycler.  Each sample was run in triplicate at three 
different concentrations.  All primer set sequences are available upon request. 
 
Statistical analysis 
Standard deviation for each sample group was calculated.  Student’s t-test was 
used to determine the confidence limits between experimental and control groups. 
 
RESULTS AND DISCUSSION 
Hh pathway activity is necessary and sufficient to regulate bnl expression and signaling 
To determine if Hh and Bnl act as independent pathways to activate neuroblast 
division in the larval brain, we evaluated bnl expression and pathway activity in brains 
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with decreased Hh signaling.  Our genetic studies had already demonstrated that the 
weak trolb22 mutation results in decreased neuroblast proliferation when combined with a 
single copy of the null hh allele hhAC (Park et al., 2003b).  Therefore we expected to 
observe reduced Hh signaling in trolb22; hhAC/+ brains.  We used quantitative Real-Time 
PCR (qRT-PCR) to assay for expression of bnl and its target gene pointed (pnt) and to 
confirm decreased expression of hh and Hh signaling by monitoring the Hh target gene 
patched (ptc).  Siblings with normal neuroblast proliferation levels were used as a 
control population.  In animals hemizygous for trolb22 and carrying the one copy of the 
null allele hhAC (trolb22; hhAC/+), hh expression and signaling were significantly reduced, 
with a reduction in expression of both bnl and its response gene pnt (Figure 2.1A, B).  
To eliminate the possibility that the alteration in bnl expression and signaling levels were 
due to the mutation in trol, we then asked if decreasing hh signaling using the 
temperature sensitive hh allele hhts2 also decreased bnl expression and signaling.  
Homozygous hhts2 animals were raised at the permissive temperature (18ºC) through 
embryogenesis and then transferred to the restrictive temperature (25ºC) upon larval 
hatching.  Heterozygous hhts2/+ animals treated to the same temperature regimen were 
used as controls.  hhts2 homozygotes had a 75% drop in hh signaling and decreased bnl 
and pnt expression compared to controls (Figure 2.1C).  BrdU analysis showed that the 
hhts2 homozygotes also had decreased neuroblast proliferation (Figure 2.1D).  These 
results indicate that the activity of the Hh pathway is necessary for normal levels of Bnl 
signaling.  We then asked whether increasing Hh signaling is sufficient to produce 
increased bnl expression and signaling activity.  The inducible hs-hh allele was used to  
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Figure 2.1.  bnl expression and signaling respond to Hh pathway activity.  (A, C, E) 
Expression of hh, ptc, bnl, and pnt were quantified by qRT-PCR in 1st instar larval brains 
at 19-20 hours post hatching (hph).  Error bars indicate standard deviation.  All samples 
were run in triplicate at three different concentrations.  (A) in trolb22; hhAC/ + animals 
relative to trolb22 control (C) in hhts2 homozygous animals relative to hhts2/ + 
heterozygotes both raised at 18°C during embryogenesis and moved to 25°C upon larval 
hatching (E) in hs-hh animals relative to hs-hh/ + heterozygotes both raised at 18°C 
during embryogenesis and moved to 25°C upon larval hatching. (B, D, F) S-phase 
neuroblasts/brain lobe were quantified and normalized to the average sibling control 
value. 
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increase hh expression; heterozygous hs-hh animals were used as sibling controls.  
Brains from homozygous hs-hh animals had a significant increase in hh expression and 
increased Hh signaling even over siblings with one copy of the inducible transgene 
(Figure 2.1E).  The increase in Hh signaling correlated with increase expression of bnl 
and pnt, as well as increased neuroblast proliferation (Figure 2.1F).  These studies 
demonstrate that bnl expression and activity in the larval brain is dependent on the level 
of Hh signaling. 
 
Bnl pathway activity determines the level of hh expression and signaling 
To ascertain if Hh signaling was similarly dependent on Bnl activity, we 
examined hh and ptc expression in animals with reduced Bnl signaling.  We first studied 
animals hemizygous for trolb22 and heterozygous for the putative null allele, bnlP1.  As 
expected, expression of both bnl and pnt dropped in the brains of these animals 
compared to controls, as did the number of BrdU labeled neuroblasts, although there was 
still some expression of the Bnl response gene pnt (Figure 2.2A, B).  Our qRT-PCR 
analysis showed that hh and ptc message levels also decline in the trolb22; bnlP1 / + 
brains (Figure 2.2A), suggesting that hh expression and signaling is dependent on Trol or 
Bnl activity.  To establish whether the drop in hh expression and signaling were due to 
the mutation in trol or decreased Bnl signaling, we examined hh and ptc expression in 
the brains of animals homozygous for bnlP1 but raised at 18°C to enable generation of 
mutant larvae.  The fact that we could obtain bnlP1 mutant larvae at 18°C but not 25°C as 
well as the detection of pnt expression in the bnlP1 mutants suggests that bnlP1 is not a  
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Figure 2.2.  hh expression and signaling respond to Bnl pathway activity.  (A, C, E) 
Expression of hh, ptc, bnl, and pnt were quantified by qRT-PCR in 1st instar larval brains 
at 19-20 hph.  Error bars indicate standard deviation.  All samples were run in triplicate 
at three different concentrations.  (A) in trolb22; bnlP1/ + animals relative to trolb22 
control (C) in bnlP1 homozygous animals raised at 18°C during embryogenesis and 
moved to 25°C upon larval hatching relative to wild-type controls (E) in UAS-bnl + / + 
hs-gal4 animals relative to UAS-bnl animals both raised at 18°C during embryogenesis 
and moved to 25°C upon larval hatching.  (B, D, F) S-phase neuroblasts/brain lobe were 
quantified and normalized to the average sibling control value. 
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true null.  For this study we used bnlP1 / + sibling animals subjected to the same 
temperature regimen.  qRT-PCR studies confirmed a 70% drop in bnl and pnt message 
levels in bnlP1 homozygotes versus control, as well as a dramatic decrease in hh and ptc 
expression (Figure 2.2C).  The number of BrdU labeled neuroblasts (4.4±0.1) 
significantly decreased compared to controls (Figure 2.2D).  The observation that only 
4-5 neuroblasts were BrdU labeled in bnlP1 homozygotes at 20 hours post hatching 
suggests that all the mitotically regulated neuroblasts require Bnl signaling to begin cell 
division, although from this data a requirement for some minimum level of Hh signaling 
cannot be eliminated.  This hypothesis will be addressed further in a following section.  
The neuroblasts labeled had cellular morphology and spatial positioning consistent with 
identification as mushroom body or ventral lateral neuroblasts.  The four mushroom 
body neuroblasts and the single ventral lateral neuroblast in each brain lobe are the only 
neuroblasts in the larval brain that are dividing upon larval hatching and divide 
continuously through larval life (Datta, 1995; Ito and Hotta, 1991).  They are also the 
only neuroblasts in the brain lobe not affected by mutations in trol that decrease 
signaling by Bnl (Datta, 1995; Park et al., 2003b).  The results of the bnl mutant studies 
also indicate that normal levels of activity of the Bnl pathway are necessary for normal 
levels of Hh signaling.  We then investigated whether increased Bnl signaling is 
sufficient to increase hh expression and signaling.  Up-regulation of Bnl signaling was 
accomplished by using a hs-GAL4 construct to drive expression of a UAS-bnl transgene.  
Animals were maintained at 18ºC to minimize expression from the hs promoter and 
activity of the GAL4 transcription factor during embryogenesis.  Upon larval hatching, 
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animals were transferred to 25ºC to induce bnl expression.  Increased expression and 
activity of bnl were confirmed by qRT-PCR and correlated with increased expression of 
both hh and ptc as well as increased numbers of BrdU labeled neuroblasts (Figure 2.2E, 
F).  Taken together, these results indicate that hh expression and activity is dependent on 
the level of Bnl signaling in the larval brain. 
 
Decreasing both Bnl and Hh signaling causes a further decrease in neuroblast 
proliferation 
The question then arose as to whether the relative ratio of Hh and Bnl signaling 
was critical for activation of neuroblast division (i.e. hh null / hh+: bnl null / bnl+ would 
work as well as hh+ / hh+: bnl+ / bnl+), or if the absolute level of signaling (compared 
to wild-type controls) is important.  To address this issue, we evaluated the amount of 
neuroblast division in trolb22 mutant animals heterozygous for both hhAC and bnlP1 and 
compared it to that in trolb22, trolb22; hhAC/+ and trolb22; bnlP1 / + animals (Figure 2.3A).  
Statistical analysis showed that the decrease in numbers of BrdU labeled neuroblasts in 
the trolb22; bnlP1 + / + hhAC brains was significantly greater than in either single 
heterozygote (p< 9 x 10-11).  qRT-PCR showed roughly equivalent decreases in 
expression of both the ligands and their target genes (Figure 2.3B).  The increased 
severity of the neuroblast proliferation phenotype in the double hh bnl heterozygote 
indicates that maintenance of the overall magnitude of Bnl and Hh signaling is essential 
for normal neuroblast proliferation. 
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Figure 2.3.  Maintenance of both Hh and Bnl signaling is required for normal 
neuroblast proliferation.  (A) S-phase neuroblasts/brain lobe were quantified and 
normalized to the average sibling control value.  Expression of hh, ptc, bnl, and pnt were 
quantified by qRT-PCR in 1st instar larval brains at 19-20 hph (B) in trolb22; bnlP1 +/ + 
hhAC animals relative to trolb22 control.  Error bars indicate standard deviation.  All 
samples were run in triplicate at three different concentrations. 
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The initiation of the Hh-Bnl feedback loop observed in the larval brain occurs during 
embryogenesis 
Thus far, our studies are consistent with a positive feedback loop between Hh 
and Bnl that regulates the level of growth factor expression.  The output of this loop then 
regulates the activation of neuroblast proliferation.  Since Hh- and Bnl-dependent 
neuroblast proliferation does not begin until 8-10 hours post hatching, we asked when 
Hh and Bnl are first expressed in the larval brain.  Larvae were collected in one-hour 
increments and the amount of hh and bnl message in the larval brain evaluated.  Both hh 
and bnl are expressed upon larval hatching, and the level of expression does not 
significantly change during the first four hours of larval life (Figure 2.4A).  We then 
asked if the level of Hh or Bnl signaling activity also remained constant during the first 
few hours of larval life.  ptc and pnt show much more dynamic temporal pattern of 
expression than the level of pathway ligand (Figure 2.4B).  Since both Hh and Bnl are 
stimulating expression of their response genes within an hour of larval hatching, the 
feedback loop could be initiated during embryogenesis, prior to larval hatching.  If the 
Hh-Bnl feedback loop is initiated during embryogenesis, then decreasing Hh signaling 
only during embryogenesis should result in lowered bnl expression and Bnl signaling in 
the larval brain immediately upon hatching.  To test this hypothesis, we used the 
temperature-sensitive hh allele, hhts2, and raised mutant animals at the restrictive (25°C) 
or permissive (18°C) temperature throughout embryogenesis.  Both experimental and 
control plates were then placed at the permissive temperature (18°C) and newly hatched 
larvae collected in a two hour window.  This  
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Figure 2.4.  Initiation of the Hh-Bnl feedback loop occurs during embryogenesis.  
Canton-S larval brains were collected in one hour increments from 0-20 hph at 25°C and 
qRT-PCR used to quantify (A) hh and bnl expression (B) ptc and pnt expression.  
Expression of hh, ptc, bnl, and pnt were quantified by qRT-PCR in (C) hhts2 homozygous 
larval brains from 0-1 hph raised at 25°C throughout embryogenesis compared to larval 
brains from 0-1 hph raised at 18°C throughout embryogenesis.  Error bars indicate 
standard deviation.  All samples were run in triplicate at three different concentrations. 
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experimental design resulted in decreased Hh signaling only during embryogenesis in 
the experimental samples.  Larval brains were dissected and assayed for levels of hh, ptc, 
bnl and pnt expression.  Our qRT-PCR results show that the levels of both bnl and its 
response gene pnt decreased in the larval brains of hhts2 animals raised at the restrictive 
temperature compared to animals raised at the permissive temperature.  The expected 
decrease in expression of hh and the Hh response gene ptc in experimental samples 
compared to controls was verified by qRT-PCR (Figure 2.4C).  This result demonstrates 
that lowering Hh signaling during embryogenesis results in decreased Bnl production 
and signaling and is consistent with the hypothesis that the Hh-Bnl feedback loop in the 
brain is already operational by larval hatching. 
 
Bnl is epistatic to Hh for the proliferation of regulated neuroblasts in the larval brain 
lobe 
So far, our results show that Bnl and Hh signal in a positive feedback loop that is 
initiated prior to larval hatching.  We next asked if the activity of both signaling 
pathways was necessary for neuroblast proliferation or if over-expression of one signal 
could rescue a deficit in the other signal.  The inducible hs-hh allele was used to increase 
hh expression in a bnlP1 homozygous mutant.  Animals were maintained at the 18°C to 
minimize expression from the hs promoter and activity of the GAL4 transcription factor 
during embryogenesis.  Upon larval hatching, animals were transferred to 25°C to 
induce hh expression.  Increased expression and activity of hh were confirmed by qRT-
PCR, and bnl expression and activity mirrored that of bnlP1 homozygotes, indicating that 
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misexpression of hh does not bypass or suppress the bnl mutant phenotype (Figure 
2.5A).  More strikingly, over-expression of hh does not rescue neuroblast proliferation in 
the bnlP1 mutant (Figure 2.5B).  As noted previously when analyzing bnlP1 homozygotes, 
we observed only 4.4 ± 0.1 neuroblasts labeled with BrdU in hs-hh; bnlP1 samples 
(indicative of the mushroom body and ventral lateral neuroblasts, which are not affected 
by Hh or Bnl signaling), compared to approximately 20 observed in normal controls and 
the 30-35 observed in hs-hh animals alone.  The failure of hh over-expression to 
overcome the effects of a bnl null mutation confirms the hypothesis that all the 
mitotically regulated neuroblasts require Bnl signaling to initiate cell division.  This data 
also suggests that Bnl activity is the signaling output of the positive feedback loop.  To 
confirm this conclusion, up-regulation of Bnl using the same hs-GAL4/UAS-bnl 
expression system described previously was examined in an hhts2 homozygous animal.  
Animals were again maintained at the 18°C to minimize expression from the hs 
promoter and activity of the GAL4 transcription factor during embryogenesis.  Upon 
larval hatching, animals were transferred to 25°C to induce bnl expression.  Increased 
expression and activity of bnl were confirmed by qRT-PCR (Figure 2.5C).  BrdU 
incorporation studies demonstrated that over-expression of bnl in a hhts2 homozygote 
resulted in significant increase (p < 0.016) in the number of S phase neuroblasts over 
that normally observed in hhts2 homozygotes at the restrictive temperature (Figure 2.5D, 
hhts2/ hhts2 show 14.7 BrdU labeled neuroblasts/brain lobe ± 0.3).  In fact, over-
expression of bnl in a hhts2 homozygote produced an over-proliferation phenotype (23.2 
BrdU labeled neuroblasts/brain lobe ± 1.6) compared to the normal 20 neuroblasts/brain 
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Figure 2.5.  Bnl is epistatic to Hh for activation of proliferation in the regulated 
neuroblasts of the larval brain lobe.  (A, C) Expression of hh, ptc, bnl, and pnt were 
quantified by qRT-PCR in 1st instar larval brains at 19-20 hph.  Error bars indicate 
standard deviation.  All samples were run in triplicate at three different concentrations.  
(A) in hs-hh; bnlP1 animals relative to bnlP1 control both raised at 18°C during 
embryogenesis and moved to 25°C upon larval hatching (C) in UAS-bnl hhts2/ hs-gal4 
hhts2 animals relative to hhts2 control both raised at 18°C during embryogenesis and 
moved to 25°C upon larval hatching.  (B, D) S-phase neuroblasts/brain lobe were 
quantified and normalized to the average sibling control value. 
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lobe observed in wild-type controls.  Altogether, these studies establish that Bnl 
signaling activity is the essential output of the Hh-Bnl feedback loop that regulates the 
activation of neuroblast proliferation. 
 
Integration of FGF and Hh signaling 
Our studies have demonstrated that Hh and Bnl act in a positive feedback loop in 
the larval brain to control the onset of neuroblast proliferation (Figure 2.6).  The 
feedback loop acts at the transcriptional level, such that Hh signaling activity is essential 
to control the level of bnl expression and vice versa.  Our double mutant analyses 
showed that an absolute level of signaling by both Bnl and Hh are required to maintain 
normal neuroblast activation, rather than other possible models that would suggest a 
certain balance of signaling activity (for example more Bnl than Hh) is sufficient 
regardless of the exact magnitude of signaling activity.  The discovery that Bnl signaling 
is the critical output of the feedback loop suggests that Hh signaling acts to maintain the 
proper level of Bnl production and signaling.  Furthermore, the observation that only the 
mushroom body and ventral lateral neuroblasts continue to divide in bnl null mutants 
regardless of the level of Hh signaling indicates that all the regulated neuroblasts, both 
optic lobe and central brain sets, require the input of the Bnl pathway to enter S phase.  
Thus the Hh Bnl feedback loop appears to control cell cycle progression in all the 
mitotically arrested neuroblasts that begin cell division in 1st instar.  The model of the 
Hh-Bnl feedback loop proposed here is most similar to the classic SHH-FGF feedback 
loop described in the vertebrate limb bud.  We do not yet know whether the regulation of  
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Figure 2.6. Model of Bnl-Hh positive feedback loop. 
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bnl expression by Hh signaling is direct or if it is mediated by another signaling pathway 
such as the Gremlin/Bone Morphogenetic Protein connection that operates in the limb 
bud (Nissim et al., 2006; Zuniga et al., 1999).  However, we have already shown that 
like the distinct domains of FGF and SHH in the limb bud (Martin, 1998), bnl and hh 
expression also occur in distinct regions of the brain lobe (Park et al., 2003b).  The fact 
that the Hh-Bnl feedback loop is activated during embryogenesis, but that the first 
regulated neuroblasts do not enter S phase until 8-10 hours after larval hatching (Datta, 
1995; Ebens et al., 1993; Truman and Bate, 1988; White and Kankel, 1978) also 
suggests that additional events must take place downstream of Bnl signaling to permit 
mitotically arrested stem cells to transit through G1 to S phase (Caldwell and Datta, 
1998; Park et al., 2003a).  One such possibility is exposure to the steroid hormone 
ecdysone, which is necessary during 1st larval instar for the initiation of neuroblast 
division a few hours later (Datta, 1999).  Both SHH and FGF2 have been shown to be 
necessary for the division of different subsets of neural stem cells in many different 
vertebrate and mammalian models and in multiple contexts (Bertrand and Dahmane, 
2006; Maric et al., 2007).  The next challenge will be to determine whether different 
molecular mechanisms tying these two signaling pathways are used for different 
developmental decisions such as progeny cell fate, initiation of cell division and 
maintenance of stem cell identity. 
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CHAPTER III 
DETERMINATION OF THE INSTABILITY OF gal4 EXPRESSION 
FROM A P-ELEMENT INSERTION IN DROSOPHILA 
 
INTRODUCTION 
 Several processes have been identified that induce genomic instability (i.e. 
irradiation, chemical alteration, and mobile elements).  The transposon or mobile genetic 
element, is a movable DNA segment that can occasionally “jump” around chromosomes 
and promote genetic rearrangement.  These mobile genetic elements were first described 
in the early 1950’s by Barbara McClintock, who pioneered genetic research in maize and 
is most noted for her work in genetic recombination (McClintock, 1953).  Her report that 
specific segments of chromosomes could “transpose” to other positions as a controlled 
phenomenon was not initially accepted by the scientific community.   It would take 
several decades for her work to become recognized. 
 Transposons are defined as segments of DNA that can change positions in the 
genome through a process called transpositional recombination, a form of genetic 
recombination.  They show modest sequence specificity of insertion site and will insert 
into a gene, causing gene disruption.  It is hypothesized that this is the most common 
source of new mutations generated in organisms.  With >50% of the maize and human 
genome being composed of transposon-like sequences, it is not hard to see that 
transposons could play an important role in genome stability and genetic variation.  
Transposons can be classified into 3 major families of transposable elements; DNA 
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transposons, viral-like retrotransposons, and Poly-A retrotransposons.  DNA transposons 
move through a cut-and-paste mechanism and remain in DNA form throughout the 
transposition process.  In contrast, both retrotransposons go through a RNA intermediate 
before being reinserted into the genome (Albornoz and Dominguez, 1999; Watson et al., 
2004).   
 Over 50 years ago a member of the DNA transposon family, the P-element, was 
identified as entering the Drosophila melanogaster population and has since spread to 
most wild and laboratory populations (Engels, 1997).  P-elements contain a transposase 
gene and long terminal repeats (LTR) that are the site of action of the Transposase.  
Transposition is restricted to the germ line where splicing of the transposase gene 
produces a functional product, unlike splicing in somatic cells where alternative splicing 
results in a repressive form of Transposase that inhibits mobility of the transposon.   The 
P-element also exists as a nonautonomous variant that contains only long terminal 
repeats and therefore can only be mobilized when Transposase is added in trans (Pinsker 
et al., 2001; Ryder and Russell, 2003).  Using these unique features, researchers have 
been able to manipulate P-elements to their advantage and they have become one of the 
most widely used genetic tools for studying gene functions in Drosophila.   
Once such P-element tool is the gal4/UAS system.  The gal4/UAS system is a 
bipartite misexpression system that is used to express a particular target gene in a tissue-
specific manner (Brand and Perrimon, 1993).  The system utilizes two P-element 
inserted transgenes for this process, the enhancer-gal4 transgene and the UAS-reporter 
transgene.  The enhancer-gal4 transgene is a construct that comprises a specific 
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promoter/enhancer sequence upstream of the yeast gal4 gene.  This sequence drives 
temporal and/or spatial expression of the yeast Gal4 transcription factor.  The UAS-
reporter transgene is a construct that comprises multiple Gal4 binding sites called 
upstream activating sequences (UAS) followed by a gene of interest, such as a reporter 
gene like gfp or lacZ.  When the enhancer-gal4 and UAS-reporter transgenes are present 
in the same fly, Gal4 will drive expression of the reporter gene in a tissue specific 
manner allowing the researcher to follow cells expressing the reporter through 
developmental and/or functional processes.  Neither gal4 nor UAS are present 
endogenously in Drosophila, which allows for temporal and spatial expression specific 
to transgene components.  These characteristics make the Gal4/UAS system a very 
powerful genetic tool for the analysis of development and function in the fly. 
 In this study, we examine a P-element generated gal4 transgene, which lacks the 
transposase gene, yet shows loss of gal4 by an unknown mechanism.  We show that the 
gal4 gene is lost stochastically from generation to generation by excision of a segment of 
the gene while retaining the rest of the P-element gene structure.  We also show gradual 
silencing of Gal4 activity in offspring from the same parental cross over a short period of 
time.  More interesting is that both mechanisms of loss can be rescued by tetracycline 
treatment of the Drosophila line suggesting a bacterial influence.  Here we explore the 
possible bacteria and mechanisms they utilize to induce gene loss/silencing of P-element 
transgenes. 
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MATERIALS AND METHODS 
Drosophila strains 
Flies were grown under standard laboratory conditions at 25°C on 
cornmeal/molasses media supplemented with yeast, unless otherwise stated.  Dr. Scott 
Selleck at University of Minnesota provided the c529 line.  The UAS-lacZ construct was 
obtained from the Bloomington Stock Center and Dr. Ginger Carney at Texas A&M 
University provided the UAS-GFP:lacZ.nls construct.  Dr. Vlad Panin at Texas A&M 
University graciously provided Wolbachia positive fly strains. 
 
PCR assay 
DNA extractions of single c529 adults or larvae were done.  PCR temperature 
conditions of 95°C for 60 sec, 60°C for 30 sec, and 72°C for 45 sec was used for 40 
cycles with the following primers:  
gal4 F2 (5′-CAGTTCTTTGTGCTGCATCGCT-3′) and  
gal4 R2 (5′-AAGTGCGACATCATCATCGGAA-3′). 
DNA extractions and PCR conditions for the detection of Wolbachia were done 
as described in (O'Neill et al., 1992) and the following primers specific for the 
Wolbachia 16S rRNA gene were used for detection in genomic DNA:  
99F (5′-TTGTAGCCTGCTATGGTATAACT-3′) and  
994R (5′-GAATAGGTATGATTTTCATGT-3′) described in (O'Neill et al., 1992).   
The following primers were used in separate PCRs as a control for the quality of 
DNA extractions (band at ~550bp):  
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F1 (5′-CCACCACGCAGTACCAGTG-3′) and  
R1 (5′- CTCCTGCCCGCCGATG -3′). 
 
Histological analysis 
 Dissection of the larval central nervous system (CNS) and salivary glands (SG) 
was performed at specific developmental stages and β-galactosidase visualization was 
achieved by fixing tissue with ET fix (1 X buffer B: formaldehyde) for 10 min at RT, 
washing three times with 1X PBST, and incubating tissue in X-gal stain for ~3 hours at 
37°C. 
 
Developmental staging 
 Larval developmental stages were identified by morphological characteristics or 
by hours post-hatching (hph). 
 
Tetracycline treatment 
 Flies were raised at 25°C on cornmeal/molasses media with or without 0.03 mg 
ml-1 tetracycline (Sigma Aldrich, cat# T3383-25G) for one generation and the allowed to 
pass through two generations before beginning experimental analysis (Erickson, 2004; 
Starr and Cline, 2002). 
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RESULTS AND DISCUSSION 
c529 is gal4 driver that labels brain neuroblasts 
c529 is a Gal4 enhancer trap line generated during a screen for expression 
patterns in the embryo, larval brain, imaginal discs, and ovary of Drosophila.  It is 
described as showing an expression pattern that labeled cells in the outer proliferative 
center (OPC), inner proliferative center (IPC), ventral ganglion (VG), in the pouch of the 
wing, and haltere discs (Manseau et al., 1997). Through further analysis, we determined 
that the c529 enhancer trap line labeled 4-5 optic lobe (OL) and/or central brain (CB) 
neuroblasts (unpublished data) (Figure 3.1).   
 
Loss of reporter gene expression over time 
 Upon characterization of the larval expression pattern in progeny generated by 
crossing a homozygous c529 male to a homozygous UAS-lacZ female, high and distinct 
expression levels were seen.  However, over time many progeny started exhibiting low 
or no expression in the larval brain.  This variation in reporter gene expression was 
somewhat puzzling since every offspring examined should be transheterozygous for 
c529 and UAS-lacZ, and therefore should exhibit the same level of expression.  There 
are several possibilities for loss of reporter gene expression, which include: loss of the 
gal4 gene in the genome either by heterozygosity in one or both parental strains, 
excision of the P-element, silencing of gal4 expression, or an accumulation of mutations 
in the gal4 gene. 
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Figure 3.1.  c529 expression profile throughout larval development.  Homozygous 
c529 female’s were crossed to homozygous UAS-lacZ male’s and the expression profile 
in the central nervous system (CNS) resolved by staining for β-galactosidase activity in 
(A) late 1st instar, (B) mid 2nd instar and (C) early 3rd instar.  (D) Fluorescent staining of 
c529 expression (green) and S-phase nuclei (red) in the CNS of a 1st instar larvae at 19-
20 hours post-hatching (hph).  Larvae were fed media containing BrdU from 16-20 hph. 
White arrowheads indicate several c529 labeled neuroblasts. 
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To address the first possibility, we looked for the presence of the P-element insertion 
that includes the gal4 gene in the c529 stock. Due to the nature of the procedure for 
introduction of P-elements into Drosophila, each P-element also includes a phenotypic 
marker, in this case w+, that allows for rapid identification of flies carrying P-element 
insertions.  Therefore, any fly that did not have a P-element insertion should have white 
eyes, while flies that contained the P-element should have red eyes.  Upon examination 
of the stock, it was determined that every fly exhibited red eyes (data not shown).  
However, it could still be possible for the c529 stock to be heterozygous for the P-
element insertion.  To test for homozygosity, we again utilized the presence of the w+ 
marker in the P-element.  If a c529 male is homozygous and is crossed to a w female, all 
progeny will exhibit red eyes.  However, if a c529 male is heterozygous and is crossed to 
a w female, 50% of the progeny will exhibit red eyes and the other 50% will exhibit 
white eyes.  The results of this experiment showed that 100% of the progeny had red 
eyes, indicating that the c529 stock is homozygous for the P-element insertion and loss 
of reporter gene expression is not due to loss of the P-element (data not shown).  
The second possibility is that the gal4 gene is being silenced by some unknown 
mechanism.  First, we wanted to determine if the loss of reporter gene expression was 
stochastic or gradual.  To address this issue, we crossed a homozygous c529 male to a 
homozygous UAS-lacZ female and dissected the CNS and salivary glands from 
developmentally staged 1st instar larvae (19-20 hours post-hatching) at 4, 5, and 6 days 
after mating.  We then compared the expression levels of the lacZ reporter gene in each 
sample. Remarkably, a dramatic decrease in the lacZ reporter gene expression is seen in 
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just two days time, going from high expression in ~5 neuroblasts and the salivary gland 
to no expression in the neuroblasts and very little expression in the salivary glands 
(Figure 3.2).  To ensure that the results are not an artifact of using the UAS-lacZ 
transgene, a second reporter line, UAS-GFP:lacZ.nls, was used and reporter gene 
expression decreased in the same manner (data not shown).  These data suggest that a 
gradual loss or silencing of gal4 gene expression/activity is occurring in progeny born 
later to the same parental flies. This then poses the question of whether silencing or loss 
of gal4 expression/activity might be occurring in the germ line cells and if reversing the 
parental genotypes would alter the results.  Therefore, we crossed a homozygous c529 
female to a homozygous UAS-lacZ male and followed reporter gene expression in the 
same fashion as previously described.  Again, a gradual loss of reporter gene expression 
is observed (data not shown).  Therefore, silencing or loss of the gal4 gene 
expression/activity is occurring independently of sex and reporter construct.  However, 
the question still remains as to whether the gal4 gene is being silenced due to detrimental 
effects of Gal4 activity, or if the gal4 gene is acquiring mutations that affect expression 
or activity.  
To address this question, we utilized the temperature sensitivity of Gal4 activity 
to determine if lowering the activity threshold would allow for continuous reporter gene 
expression, albeit at a lower level.  Two crosses were set up of homozygous c529 male’s 
and homozygous UAS-lacZ female’s, which were allowed to mate at 18°C and 22°C, 
respectively. At 18°C, lacZ expression in developmentally staged 1st  
 63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.  Loss of UAS-lacZ expression in F1 progeny from same parental cross.  
A homozygous c529 male was crossed to a homozygous UAS-lacZ female and 
expression levels examined in the (A, B, C) central nervous system and (A′, B′, C′) 
salivary glands of developmentally staged 1st instar larvae (19-20 hours post-hatching) 
generated on the (A, A′) 4th, (B, B′) 5th, and (C, C′) 6th day after mating.  All samples 
were processed for the same time period with the same staining protocol.  Parental cross 
and F1 larvae were raised at 25°C. 
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instar larvae (38-40 hours post-hatching) was followed at 8, 10, and 12 days after 
mating.  At 22°C, lacZ expression in developmentally staged 1st instar larvae (28.5-30 
hours post-hatching) was followed at 6, 8, and 10 days after mating.  Both crosses, at 
18°C and 22°C, showed a decrease in lacZ expression over time, similar to that seen at 
25°C (Figure 3.3). These data suggest that the loss of reporter gene expression in 
progeny from the same parental cross over time is not due to a detrimental effect of Gal4 
activity since the same phenotypic anomaly is also seen at temperatures that permit 
limited Gal4 activity.   
Next, we looked for possible mutations/deletions of the gal4 gene by PCR 
amplification of a specific region of gal4 in single flies of the c529 stock.  We extracted 
genomic DNA from 50 individual flies, 25 male and 25 female, and performed PCR 
analyses on each fly.  Fourty two out of 50 Genomic DNA extractions were determined 
to be of good quality by PCR analysis with the control primers F1 and R1 that amplify a 
segment of the endogenous trol gene.  Then, PCR reactions with primers specific for the 
C-terminal region of gal4 were carried out on the 42 high-quality samples.  Analysis of 
the PCR products demonstrated that only 4 out of 42 (9.5%) flies contained this region 
of the gal4 gene (Figure 3.4).  This is a surprising result since we previously reported 
that all of the C529 stock contained flies with red eyes, therefore indicating presence of 
the P-element insertion.  These data suggest that there is not only gradual loss of Gal4 
activity but also loss of gal4 coding sequences.   
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Figure 3.3. Loss of UAS-lacZ expression in F1 progeny is not due to detrimental 
effect of Gal4 activity. Two crosses were set up of a homozygous c529 male and a 
homozygous UAS-lacZ female, which were allowed to mate at 22°C or 18°C, 
respectively. (A, B, C) The central nervous system (CNS) of developmentally staged 1st 
instar larvae (28.5-30 hours post-hatching) raised at 22°C were dissected from progeny 
produced on the (A) 6th, (B) 8th, and (C) 10th day after mating and activation of lacZ 
expression produced by Gal4 transcriptional activity examined by staining for β-
galactosidase activity.  (D, E, F) The central nervous system of developmentally staged 
1st instar larvae (38-40 hours post-hatching) raised at 18°C were dissected from progeny 
produced on the (D) 8th, (E) 10th, and (F) 12th day after mating and activation of lacZ 
expression produced by Gal4 transcriptional activity examined by staining for β-
galactosidase activity. 
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Figure 3.4.  Loss of a portion of the gal4 gene from the genome of the c529 stock.  
PCR reactions of genomic DNA extracted from individual flies from the c529 stock 
using primers that amplify a segment in the C-terminal region of gal4 and control 
primers that amplify a segment of the endogenous trol gene are shown.  Individual 
reactions were preformed with each primer set, then combined together during 
resolution, respectively.  Lane 1 shows a PCR product at ~1.5 kb which represents the 
C-terminal region of gal4.  Lane 2 does not show a gal4 amplification product. 
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Rescue of gal4 instability and reporter gene expression 
It has been shown that infection of Drosophila with the bacterial endosymbiont, 
Wolbachia pipientis, rescues the defective fertility phenotype in Sex-lethal (Sxl) mutants 
(Starr and Cline, 2002) indicating that Wolbachia infection can affect gene expression or 
function.  Furthermore, a recent report documented Wolbachia infection of a large 
portion of Drosophila stocks present in a major community stock center (Clark et al., 
2005).  Due to the unique nature of the phenotype discussed above it postulated that a 
parasitic infection might be the cause.  Therefore, I took a subpopulation of the c529 
stock and raised it at 25°C on cornmeal/molasses media with the addition of the 
antibiotic tetracycline (0.03 mg ml-1) for one generation, then allowing for a two-
generation recovery time.  By treating the flies with an antibiotic, it would be possible to 
“cure” the stock of any bacterial infection that could be causing the novel gal4 
phenotype.  After antibiotic treatment, genetic and phenotypic analyses of c529 
segregation and activity were followed for two generations compared to the original 
“untreated” c529 stock. The experimental design is explained in greater detail in Figure 
3.5.  Assuming that the P-element in c529 follows Mendelian segregation and that the 
parental stocks are homozygous and their gal4 expression/activity is at 100%, the F1 
progeny would be expected to show presence of the gal4 gene and β-galactosidase 
activity at 100%.  The F2 progeny would be expected to show presence of the gal4 gene 
and β-galactosidase activity at 50%. However, when the “untreated” c529 stock was 
analyzed F1 progeny show presence of the gal4 gene and β-galactosidase activity at 58% 
and 10%, respectively and F2 progeny showed presence of the gal4 gene and β- 
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Figure 3.5.  Experimental design for examining Mendelian segregation and activity 
of the c529 line. A homozygous c529 female, tetracycline treated or untreated control, 
was crossed to a homozygous UAS-lacZ male.  From the progeny (F1) generated, CNS 
and salivary glands were dissected from 10 climbing 3rd instar larvae and stained for β-
galactosidase activity.  Individual genomic DNA extractions and PCR analyses for the 
presence of gal4 in the remaining larval bodies were also done.  Then 10 adult female F1 
progeny, with one genetic copy of c529 and UAS-lacZ each, were backcrossed to a 
homozygous UAS-lacZ male. From the progeny (F2) generated in each cross, CNS and 
salivary glands were dissected from 10 climbing 3rd instar larvae and stained for β-
galactosidase activity.  Individual genomic DNA extractions and PCR analyses for the 
presence of gal4 in the remaining larval bodies were also done. 
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galactosidase activity at 73% and 2%, respectively.  When c529 is treated with 
tetracycline, F1 progeny show both presence of the gal4 gene and β-galactosidase 
activity at 100% and F2 progeny showed presence of the gal4 gene and β-galactosidase 
activity at 73% and 43%, respectively (Figure 3.6).  Therefore, tetracycline treatment 
rescues loss of a portion of the gal4 gene and the resulting β-galactosidase activity. 
However, an unexpected result was observed in the percentage of F2 offspring 
that were PCR-positive for the gal4 gene.  Approximately 73% of both of the untreated 
controls and tetracycline treated lines contained the gal4 gene instead of the expected 
Mendelian ratio of 50%.  The observed percentage of gal4 containing F2 progeny is 
consistent with the hypothesis that the c529 line contains two copies of the P-element in 
its genome instead of only one copy, and that these two copies segregate independently 
in a Mendelian fashion.  The presence of two insertions is not at all unusual since P-
elements may insert into the genome multiple times during generation of transgenic 
lines.  Furthermore, the possibility that there are two gal4 carrying P-element insertions 
in c529 also suggests that the gal4 gene causing the larval expression pattern I am 
monitoring is being lost at an even higher frequency than the data would initially 
indicate.  The loss of the larval brain-expressed gal4 would be hidden in some animals 
by the presence of the gal4 gene in the second P-element insertion.  If this is true, we 
would expect to observe the presence of gal4 at a higher frequency that β-galactosidase 
activity in the larval brain, which is indeed observed.  Taken together, these data suggest 
that the original c529 stock is infected with a bacterium that is the causative agent in 
genomic/phenotypic loss of the gal4 gene.   
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Figure 3.6. Tetracycline treatment rescues the instability of the gal4 gene and loss 
of β-galactosidase activity.  The F1 progeny generated from the parental cross were 
analyzed for β-galactosidase activity in the CNS and salivary glands and presence of the 
gal4 gene from the remaining larval body of 10 climbing 3rd instar.  From Ten F1 
backcrosses, 10 climbing 3rd instar larvae from each cross were analyzed for β-
galactosidase activity in the CNS and salivary glands and presence of the gal4 gene from 
the remaining larval body.  Values shown in bold are the percentage of larvae analyzed 
that tested positive for gal4 and stained for β-galactosidase activity, which is compared 
to the expected percentages, not in bold, assuming proper Mendelian segregation, gene 
expression, and enzymatic activity.  Both the c529 stock treated with tetracycline and 
untreated controls were analyzed. 
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Identification of bacterial infection 
Since treatment with tetracycline rescues presence of the gal4 gene and 
expression of the lacZ reporter gene, a bacterial parasite is most likely the cause. To 
date, Wolbachia pipientis is the only bacterium that has been shown to alter the 
phenotype of a Drosophila mutant.  Therefore, we wanted to determine if the bacterial 
infection in c529 was in fact a Wolbachia infection.  Primers specific for Wolbachia 
detection in genomic DNA extractions of the host were used (O'Neill et al., 1992).  A 
known Drosophila strain infected with Wolbachia was used as a positive control.  Upon 
PCR analysis, it was determined that neither c529 with or without treatment with 
tetracycline showed infection by Wolbachia (Figure 3.7).  This presents as an interesting 
result because our data suggest that an unknown bacterium is the cause of a mechanism 
of genomic instability novel to the Drosophila community.   
 In August 2005, a manuscript describing the “widespread prevalence of 
Wolbachia in laboratory stocks and the implications for Drosophila research” was 
published from Timothy Karr’s laboratory (Clark et al., 2005; Clark and Karr, 2002).  
Like Karr’s findings, the results presented here serve to inform the Drosophila 
community of another, yet unknown, bacterium that has the potential to alter not only 
the phenotype but also the genotype of a host P-element transgene when infected.  
Further analysis to determine the type of bacterial infection and mechanism/mechanisms 
utilized by that bacterium to alter host functions is currently under way. 
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Figure 3.7.  Bacterial infection is not Wolbachia pipientis. PCR reactions of genomic 
DNA extracted from a Wolbachia infected Drosophila strain and the c529 stock before 
and after tetracycline treatment using primers that amplify a segment specific to the 
Wolbachia 16S rRNA gene and control primers that amplify a segment of the 
endogenous trol gene are shown.  Individual reactions were preformed with each primer 
set, then combined together during resolution, respectively.  Lane 1 shows a PCR 
product at ~ 0.9 kb which represents Wolbachia specific 16S rRNA gene.  Lane 2 and 3 
shows no PCR product for the Wolbachia specific 16S rRNA gene. 
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CHAPTER IV 
CONCLUSIONS AND FUTURE DIRECTIONS 
  
 I am interested in understanding the mechanisms employed in the activation of 
post-embryonic neural stem cell (neuroblast) proliferation.  I have used Drosophila 
melanogaster as a model system to address questions on how specific signaling 
molecules instruct neuroblasts to exit a quiescent state and begin proliferation.  More 
specifically, I have focused my research on the involvement of the Branchless and 
Hedgehog signaling pathways in the activation of neuroblast proliferation during a 
second wave of neurogenesis that occurs in larval development.  By utilizing the unique 
features of larval neurogenesis, I hoped to elucidate the activation mechanism of 
neuroblast proliferation by Hedgehog and Branchless signaling.  With this knowledge, I 
not only would gain a greater understanding of basic signaling mechanisms but also 
contribute significantly to the field of stem cell biology. 
 
HEDGEHOG AND BRANCHLESS SIGNAL THROUGH A POSITIVE 
FEEDBACK LOOP TO ACTIVATE NEUROBLAST PROLIFERATION  
The adult Drosophila central nervous system (CNS) is generated through two 
phases of neurogenesis.  The first phase of neurogenesis involves initial identification of 
the neurogenic region in the embryo followed by neural stem cell (neuroblast) 
specification and rapid generation of the basic brain and ventral nerve cord structural 
morphology.  The second phase of neurogenesis occurs during larval life and 
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encompasses reactivation of proliferation in neuroblasts that entered into a quiescent 
state in late embryogenesis.  Through exploitation of larval neurogenesis (second phase), 
I was able to examine activation of post-embryonic neural stem cell division.  My 
analysis uncovered a positive feedback loop between two signaling molecules, 
Fibroblast Growth Factor (FGF) and Hedgehog (Hh), which is required for proper 
activation of post-embryonic neuroblast proliferation (Chapter II). 
Both FGF and Hh signaling have been extensively studied and their involvement 
implicated in numerous processes including cell growth, proliferation, wound healing, 
and tumorigenesis.  More specifically, their roles in development and homeostasis of the 
central nervous has been widely scrutinized (Ahn and Joyner, 2005; Dono, 2003; Ruiz i 
Altaba et al., 2002).  Previous work in our lab showed that hh and the Drosophila FGF, 
branchless (bnl), mutants, in a trol mutant background, negatively affected post-
embryonic neuroblast proliferation (Park et al., 2003b).  This initial look at growth factor 
signaling and neuroblast proliferation brought to light many questions.  Do the Hh and 
Bnl pathways signal in a dependent or independent manner?  Do all of the brain 
neuroblasts require both Hh and Bnl signaling to exit quiescence or can signals from 
only one pathway suffice?   
To address these questions, I utilized a histological assay to assess neuroblast 
proliferation and qRT-PCR to monitor the interaction between the bnl and hh signaling 
pathways.  I found that when Bnl signaling was decreased, causing a defect in neuroblast 
proliferation, that hh expression and activity, determined by expression of the Hh target 
gene patched, were also negatively affected.  The same was true when Hh signaling was 
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decreased, showing the same neuroblast proliferation phenotype.  bnl expression and 
activity, determined by expression of its target gene pointed, were negatively affected. 
The converse over-expression experiments again demonstrated dependence, this time in 
a positive manner, between the hh and bnl signaling pathways.  These studies suggest 
that hh and bnl expression and signaling are inter-dependent in the larval CNS.  The feed 
back loop I observed is partially consistent with interactions seen between Shh and 
specific FGFs in several areas of the vertebrate brain.  Embryos injected with both 
FGF3- and FGF8-morpholinos show a decrease in shh expression in the hypothalamus 
of the developing Zebrafish brain.  Expression analysis examined in the ventral 
thalamus, adjacent to the hypothalamus, showed that only tiggywinkle hedgehog (twhh) 
is regulated by FGF3 and FGF8 activity. This suggests that FGF3 and FGF8 regulate shh 
and twhh expression in a region specific manner (Bertrand and Dahmane, 2006; Walshe 
and Mason, 2003).    
True FGF-Hh positive feedback loops have been shown in development of the 
vertebrate limb bud and chick retinal regeneration (Niswander et al., 1994; Spence et al., 
2007).  This is the first time that a true Hh-FGF feedback loop has been demonstrated in 
the invertebrate or vertebrate CNS.  However, the question still remains as to whether all 
of the quiescent brain neuroblasts receive the same signal or if there are neuroblasts that 
only respond to one signaling molecule?  A recent study from the Joyner lab showed that 
two neurogenic regions of the post-embryonic vertebrate brain, the dentate gyrus and 
subventricular zone (SVZ), show activation of quiescent neural stem cells, called 
astrocytes, in response to Shh signaling (Ahn and Joyner, 2005).  From these data, you 
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could therefore postulate that it would seem reasonable for all neuroblasts in the same 
region to require the same signal. If both FGF and Hh signaling directly activated 
neuroblast proliferation, then defects in neuroblast proliferation by loss of one signaling 
pathway should be partially or fully rescued by over expression of the other signaling 
pathway.  However, if only one signaling pathway directly activates neuroblast 
proliferation, then a defect in that same pathway would not be rescued by over 
expression of the other pathway.  In fact, that is exactly what we see for activation of CB 
and OL neuroblasts in the Drosophila 1st larval instar brain.  In null bnl homozygous 
mutants, proliferation is seen in only the MB and VL neuroblasts.  Amazingly, when hh 
is over expressed in the same null bnl mutants, none of the CB or OL neuroblasts are 
induced to proliferate, leaving the MB and VL neuroblasts as the only cells proliferating.  
As expected, the opposite finding is seen when bnl is over expressed in hhts2 mutants, not 
only is neuroblast proliferation fully rescued, but expression of hh and hh target genes is 
upregulated, further evidence of Bnl and Hh inter-dependent signaling. 
Elucidation of this FGF-Hh feedback loop with respect to regulation of 
Drosophila neuroblast proliferation is significant because it could help shed light on the 
mechanisms used to induce proliferation of adult neural stem cells in the higher systems 
like the mammalian or vertebrate brain, which is sorely lacking.  Currently, there have 
been two main areas of neurogenesis identified in the vertebrate adult brain.  The 
subventricular zone (SVZ) of the lateral ventricle and the dentate gyrus subgranular zone 
(SGZ) within the hippocampus (Cayuso and Marti, 2005; Temple and Alvarez-Buylla, 
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1999).  In vitro and in vivo, studies have been done on neural stems cells of these areas 
to define the factors that guide proliferation, differentiation, and survival.   
Many factors important in development of the adult brain persist after 
embryogenesis and function in the adult brain, which make these factors an attractive 
focus for possible involvement in regulation of neural stem cell proliferation.  In the 
SVZ, in vitro or in vivo stimulation of neural stem cell proliferation by FGF-2, EGF, 
VEGF, TGFα or Shh have been shown.   Most of the same molecules, except TGFα and 
Eph/ephrin, have also been shown to increase neural stem cell proliferation in the 
dentate gyrus using in vitro or in vivo methods (Alvarez-Buylla and Lim, 2004; Alvarez-
Buylla et al., 2002; Craig et al., 1996; Gage, 2000; Gritti et al., 1999; Wagner et al., 
1999).  However, the mechanism/s of growth factor interactions/signaling in the 
initiation of neural stem cell proliferation has not been widely studied.   
The first evidence showing induction of neural stem cell proliferation and 
neurogenesis by a growth factor was done in vitro with the isolation of proliferating cells 
from the striatum of the adult mouse brain (Reynolds and Weiss, 1992).When cells were 
cultured in serum free media plus Epidermal Growth Factor (EGF), most cells died in 
culture.  However a small percentage of the cells instead underwent proliferation. 
Unfortunately, addition of basic Fibroblast Growth Factor (bFGF), Platelet-derived 
Growth Factor (PDGF), or Nerve Growth Factor (NGF failed to induced the same 
response.  After ~8 days in vitro (DIV) all of the EGF responsive proliferating cells 
detached from the culture plate and associated together in a sphere, called a neurosphere. 
The proliferating cells initially stained positive for the neural stem cell marker Nestin, an 
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intermediate filament found in neuroepithelial cells.  It was then postulated that the cells 
that formed the neurosphere were ependymal stem cells located in the striatum.  After 
~25 DIV, cells were seen starting to migrate out of the neurosphere and marker analysis 
determined that cells with the morphological and antigenic property of both neurons and 
astrocytes were being generated.  Adult neurogenesis does not occur in the striatum after 
approximately 1 day post-natal, however these data suggested that embryonic 
populations of neural stem cells survive in the adult striatum in a quiescent state and are 
shown to be responsive to EGF signaling in vitro.  Similar experiments done in other 
areas of the adult brain identified multipotent stem cells present in the subventricular 
zone of the lateral ventricle, the 3rd and 4th ventricles, and all regions of the spinal cord 
(Morshead et al., 1994; Weiss et al., 1996).  All were responsive to either EGF or an 
EGF/bFGF combination.   
Another very elegant set of in vivo experiments showed that injection of EGF or 
bFGF in the subventricular layer (SVZ) of the lateral ventricle increased the number of 
proliferating cells, although at differing levels, ~16- and 2.4-fold, respectively.  This 
increase in cell proliferation was shown to be an increase in proliferation of neural stem 
cell that were previously quiescent, shown by the large increase in the number of 
neurospheres formed in vitro with prior in vivo injection of either EGF or bFGF, 370% 
and 49% increase, respectively. These findings go in line with the effects I see in growth 
factor stimulation of Drosophila post-embryonic neuroblasts although only at the level 
of stimulation of proliferation through growth factor signaling.  My findings advance our 
knowledge of growth factor signaling and stem cell activation by looking at not only
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stimulation of neural stem cell proliferation but also the mechanisms underlying the 
initial activation of cell division.  I am the first to show that FGF and Hh signal through 
an inter-dependent pathway by way of regulation of growth factor and pathway 
component expression.  Many of the studies that have looked at growth factor regulation 
of neural stem cell proliferation have looked at either FGF or EGF signaling.  Only 
limited studies have been done with regards to other growth factor involvement in neural 
stem cell proliferation.  To date only a handful of studies have shown that Shh may play 
a role in stimulation of adult neural stem cells in the vertebrate brain (Lai et al., 2003; 
Palma et al., 2005).  However, correlation between Shh signaling and other signaling 
pathways known to be involved in neural stem cell proliferation has yet to be examined. 
This leaves a huge gap in our knowledge of neural stem cell regulation.  I believe that 
my work has provided a major stepping-stone for guidance of future research in 
elucidating the mechanisms involved in neural stem cell proliferation.  I also believe that 
my model of FGF and Hh pathway interaction in stimulation of quiescent neural stem 
cells may be conserved in the vertebrate system, shown not only by the conservation of 
pathway components but the evidence of functional conservation seen in processes like 
embryonic patterning and organ development between flies and vertebrates. 
To date, elucidation of the signaling mechanisms/interactions utilized by growth 
factors to stimulate quiescent neural stem proliferation has yet to be addressed.  
Although still in its infancy, understanding neural stem cell regulation poses as possibly 
one of the most exciting areas of stem cell biology at present.  Many neurological 
diseases involve the death of specific types of neurons required for proper neurological 
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function.  Therefore, understanding how to manipulate endogenous neural stem cells to 
generate new neurons for repaired neurological function is tantamount to the ultimate 
goal for neural stem cell researchers.   
Since the introduction of stem cells to the scientific community, it has been 
shown that almost every organ in the body contains some form of stem cells (Mimeault 
et al., 2007).  This begs the question as to whether stem cell regulation in one 
environment is similar to or completely different from regulation in a different 
environment.  Extensive research has been done on a wide variety of stem cell types 
including germ-line, embryonic, and hematopoietic stem cells, for example.  In the 
hematopoietic system, hematopoietic stem cells (HSC) are stem cells that give rise to all 
blood cell types in the body (Metcalf, 1998a).  Most of the information known about 
HSCs involves the elucidation of their origin and lineage tracing.  A substantial amount 
of research is also devoted to the factors that regulate differentiation and development of 
mature hematopoietic cells.  Several growth factors/cytokines have been shown to 
regulate formation of progenitor cells from stem cells.  IL-1, IL-3, IL-6, SCF, and G-
CSF are just a few known regulators of HSC proliferation. Each factor has been shown 
to regulate HSC populations, however it has been shown that combinations of factors are 
required for proliferation of HSCs (Metcalf, 1993; Metcalf, 1998b).  Only limited 
expansion of these findings with regards to pathway interactions has been looked at to 
date.  Again, a major aspect of activation of stem cell proliferation remains to be 
elucidated.  Therefore, a molecular dissection of the activation of stem cell proliferation 
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needs to be undertaken.  The work that I have presented in this dissertation provides 
direction for future research throughout the stem cell community.  
 
Future directions 
 I have clearly established the presence of a positive feedback loop between Hh 
and Bnl in the larval CNS.  I have also shown that Bnl signaling activation is required by 
all of the quiescent neuroblasts to begin proliferation.  These results provide a strong 
foundation for elucidating the complete mechanism of action taken when Bnl and Hh 
signal to quiescent neuroblasts, inducing them into a proliferative state.  Several aspects 
of this signaling model need to be addressed. First and foremost, I believe that the 
identification of the Hh and Bnl producing/responding cells is a key piece of information 
missing from the puzzle that would greatly help in understanding the requirements 
needed for neural stem cell reactivation.  It is possible, even though Bnl and Hh 
signaling have been shown to induce activation of neuroblast proliferation, that neither 
Bnl nor Hh directly signal to a neuroblast.  Another player could be involved.   
Secondly, a way to label individual or small groups of neuroblasts in the 1st instar 
brain is needed. Neuroblast molecular marker maps have been published for embryonic 
and post-embryonic (3rd instar) neuroblasts, however none of the molecular markers we 
have tried are visible in the 1st instar CNS (Doe, 1992; Urbach and Technau, 2003a; 
Urbach and Technau, 2003b).  This would allow for finer dissection of the mechanism of 
growth factor signaling at a signal cell level. 
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 Another facet of the Bnl-Hh feedback loop that needs to be addressed is the 
mechanism of pathway interaction.  Does Bnl signal through the RAS/MAP Kinase 
cascade to regulate hh and/or hh target gene expression at the transcriptional level?  Or 
do the Bnl and Hh pathways interact through an unknown intermediate?  Further 
elucidating the interactions between Bnl and Hh will not only increase our understanding 
of signal transduction pathways and development in Drosophila, but also help advance 
the field of stem cell biology. 
 
HOST-PARASITE INFECTION CONTRIBUTES TO gal4 INSTABILITY IN P-
ELEMENT INSERTION 
 Almost every species on Earth in some way or another relies on a Host-parasite 
interaction.  These interactions exist in many forms, which in some cases go completely 
unnoticed or in others are extremely detrimental to the host.  Therefore, the study of the 
effects of parasite infection on host competence is a broad and critical field of research.  
I have examined the effects of bacterial infection on genomic stability in Drosophila 
melanogaster.  My analysis discovered a unique host-parasite interaction that causes, by 
an unknown mechanism, P-element instability through partial excision/loss of segments 
of the P-element in the host genome (Chapter 3). 
  P-elements are transposable forms of DNA whose unique features have been 
harnessed in the development of the GAL4/UAS system (Brand and Perrimon, 1993).  
The system allows for spatial and temporal expression of a particular target gene within 
the Drosophila organism.  A Drosophila P-element insertion line, called c529, 
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containing the yeast gal4 gene, unexpectedly showed loss of reporter gene expression.  
This loss was more specifically observed to be a gradual loss in reporter expression in 
progeny from the same parental cross over just a few days time.  I also observed 
genomic loss of a segment of the gal4 gene in the c529 stock.  There are several 
possibilities for this phenomenon, which include loss of the gal4 gene in the genome 
either by heterozygosity in either parental strain, excision of the P-element, silencing of 
gal4 expression, or an accumulation of mutations in the gal4 gene, to name a few. 
 Through genetic and phenotypic analysis, I showed that loss of a segment in the 
gal4 gene and reporter gene expression was not due to parental heterozygosity, whole P-
element excision, or detrimental affects of Gal4 activity.  Since the loss of the gal4 gene 
and reporter activity could not but attributed to some of these events, it was proposed 
that a secondary agent could be the effector.  Interestingly, a published study from the 
Cline lab showed alteration of the Sex lethal (Sxl) mutant phenotype upon infection with 
the bacterial endosymbiont Wolbachia pipientis (Starr and Cline, 2002).  This study 
suggested that Wolbachia could affect gene expression/function.  More recently, another 
study published from the Karr lab showed that a large proportion of the stocks from a 
widely used Drosophila stock center (Bloomington Stock Center) were infected with 
Wolbachia (Clark et al., 2005).  I then asked if a bacterial infection could be the 
causative agent in the establishment of this unique genomic instability and whether 
treatment with the antibiotic, tetracycline, could rescue this phenotype.  After “curing” 
with tetracycline, I showed that loss of gal4 and reporter activity was rescued.  I believed 
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that Wolbachia was the most likely candidate for infection. However, PCR analysis 
showed that the bacterial infection was not Wolbachia.   
The results presented here serve to inform the Drosophila community of another, 
yet unknown, bacterium that has the potential to alter not only the phenotype but also the 
genotype of a host P-element transgene when infected. 
 
Future directions 
 I have established that a bacterial infection causes, by some unknown 
mechanism, the gradual loss of reporter gene activity and loss of a segment of the gal4 
gene in a P-element generated Drosophila line, called c529.  First, the identification the 
infecting bacterium through a wide spread PCR analysis is crucial to discerning possible 
mechanisms employed in upon infection.   
Secondly, to molecularly decipher loss of only a segment of the gal4 gene the 
complete sequence of excised DNA must be determined.  Lastly, P-element insertional 
analysis should be carried out on the c529 line to determine if more than one P-element 
is inserted and where they are present in genome. 
 
CONCLUSIONS 
 Using powerful genetic and molecular tools available in Drosophila 
melanogaster, I have participated in research that has significantly added to the field of 
stem cell biology. These studies have provided new insight into the activation of 
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proliferation in post-embryonic neural stem cells and laid the solid foundation for 
understanding the basic signaling pathway interactions. 
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APPENDIX A 
INHIBITION OF PROSTATE CANCER PROLIFERATION BY 
INTERFERENCE WITH SONIC HEDGEHOG GLI1 SIGNALING* 
 
PERLECAN MODULATES SONIC HEDGEHOG SIGNALING IN ADVANCED 
PROSTATE CANCER 
Advanced Prostate cancer is one of the most clinically significant neoplasias in 
American men, killing about 27,000 a year. It is imperative to find therapies that target 
transition to metastasis and increase survival rate. A hallmark of tumorigenesis is the 
misregulation of signaling pathways that are utilized during development, and are 
normally downregulated in adults. SONIC HEDGEHOG (SHH) signaling has an 
important role in prostate development (Ingham and McMahon, 2001) and has been 
shown to be upregulated in other types of cancer, such as lung cancer (Watkins et al., 
2003). Our studies in the Drosophila brain show that the Drosophila homolog of SHH 
signaling is modulated by the Extracellular matrix proteoglycan PERLECAN. The single 
human PERLECAN gene maps to the CABP locus, which has been identified by human 
genetics studies as having an increased risk for prostate cancer and brain cancer (Janer et 
al., 2003).  
___________ 
*Reprinted with permission from Sanchez, P., Hernandez, A.M., Stecca, B., Kahler, 
A.J., DeGueme, A.M., Barrett, A., Beyna, M., Datta, M.W., Datta, S., and Ruiz I Altaba, 
A. 2004.  Inhibition of prostate cancer proliferation by interference with SONIC 
HEDGEHOG GLI1 signaling.  PNAS 101, 12561-12566.  Copyright 2004 © by The 
National Academy of Sciences of the USA. 
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Furthermore, there has been evidence of PERLECAN upregulation in prostate cancer cell 
lines (Iozzo et al., 1994).  We hypothesize that PERLECAN modulates SHH signaling 
and regulates SHH-dependent cell proliferation in advanced prostate cancer.  
 
CONTRIBUTIONS 
My contribution to the work in (Sanchez et al., 2004) involved analysis of the 
Shh signaling pathway components in prostate tumors and matched normal tissue 
samples taken from six patients.  I assisted Ana Maria Hernandez, a graduate student in 
Dr. Datta’s lab, by performing several qRT-PCR experiments of both sample types to 
determine the expression levels of Shh, PTCH1, and GLI1/2/3 (Table A-2).  From these 
data, it is suggested that overall expression levels of all pathway components increased 
(between 1.5- and ≈300-fold) in tumors sample compared to matched normal prostate 
tissue.  However, there is some noted variability between tumor samples, which could be 
attributed to the known heterogeneity of prostate cancer. 
 
ABSTRACT 
Prostate cancer is the most common solid tumor in men, and it shares with all 
cancers the hallmark of elevated, nonhomeostatic cell proliferation. Here we have tested 
the hypothesis that the SONIC HEDGEHOG (SHH)-GLI signaling pathway is 
implicated in prostate cancer. We report expression of SHH-GLI pathway components in 
adult human prostate cancer, often with enhanced levels in tumors versus normal 
prostatic epithelia. Blocking the pathway with cyclopamine or anti SHH antibodies 
inhibits the proliferation of GLI1+/PSA+ primary prostate tumor cultures. Inversely, SHH 
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can potentiate tumor cell proliferation, suggesting that autocrine signaling may often 
sustain tumor growth. In addition, pathway blockade in three metastatic prostate cancer 
cell lines with cyclopamine or through GLI1 RNA interference leads to inhibition of cell 
proliferation, suggesting cell autonomous pathway activation at different levels and 
showing an essential role for GLI1 in human cells. Our data demonstrate the dependence 
of prostate cancer on SHH-GLI function and suggest a novel therapeutic approach. 
 
INTRODUCTION 
SONIC HEDGEHOG (SHH) signaling has been implicated in different aspects 
of animal development, acting through several components, including the 
transmembrane proteins PATCHED1 (PTCH1) and SMOOTHENED (SMOH), to 
activate the GLI zinc-finger transcription factors (Ingham and McMahon, 2001; Ruiz i 
Altaba et al., 2002). In addition, we and others have shown that SHH signaling is 
implicated in a number of tumors (Pasca di Magliano and Hebrok, 2003; Ruiz i Altaba et 
al., 2002), such as basal cell carcinomas (Dahmane et al., 1997; Hahn et al., 1996; 
Johnson et al., 1996), medulloblastomas (Berman et al., 2002; Dahmane et al., 2001), 
gliomas (Dahmane et al., 2001), sarcomas (Hahn et al., 1996; Stein et al., 1999), tumors 
of the digestive tract (Berman et al., 2003), small cell lung cancers (Watkins et al., 
2003), and pancreatic carcinomas (Thayer et al., 2003). To date there is no direct 
evidence linking SHH signaling to prostate cancer, the most common solid cancer in 
men (Nelson et al., 2003), although we have found that sporadic prostate tumors express 
GLI1 (Dahmane et al., 2001), a reliable marker of SHH signaling (Hynes et al., 1997; 
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Lee et al., 1997). This observation allowed us to propose the hypothesis that the SHH-
GLI pathway participates in prostate cancer (Dahmane et al., 2001). Consistently, Shh 
signaling has been found to be essential for prostate patterning and development (Barnett 
et al., 2002; Berman et al., 2004; Freestone et al., 2003; Lamm et al., 2002; Podlasek et 
al., 1999; Wang et al., 2003), and genetic mapping data has revealed that at least two key 
components of the SHH-GLI pathway [SMOH and SUPPRESSOR OF FUSED 
(SUFUH)] are located in chromosomal regions implicated in familial human prostate 
cancer (Easton et al., 2003; Xu et al., 2003). Here we have tested the involvement of 
SHH-GLI signaling in prostate cancer. 
 
METHODS 
Cell Lines and Primary Cultures 
The PC3, LNCaP, and DU145 cell lines (Horoszewicz et al., 1980; Kaighn et al., 
1978; Stone et al., 1978) were purchased from American Type Culture Collection and 
grown as specified. All primary prostate tumors were obtained following approved 
protocols. Tumors in PBS were chopped with a razor blade and incubated with Papain 
for 1 h at 37°C, they were then dissociated by passing them through a fire-polished 
pipette and washed several times in serum containing media. All dissociated primary 
tumors were plated in polyornithinand laminin-treated p16 plates in DMEM-F12 with 
10% FBS at ~30,000 cells per p16 well. Primary cultures were used 2-4 days after 
plating, when the cells reached 60-70% confluence. 
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In Situ Hybridization and Immunocytochemistry 
Immunocytochemistry was performed with anti-BrdUrd (Beckton Dickinson), 
anti- SHH (Santa Cruz Biotechnology), and anti-Ki-67 (DAKO), using FITC- or 
horseradish peroxidase (HRP)-conjugated secondary antibodies (Boehringer Mannheim) 
as described (Dahmane et al., 2001). For tissue arrays, slides were baked and 
deparaffinized before blocking of endogenous peroxides. They were then developed with 
HRPconjugated secondary antibodies and diaminobenzidine (DAB). In situ 
hybridizations on frozen sections with digoxygenin-labeled antisense RNA probes for 
GLI1, PTCH1, and SHH and a sense control GLI1 were as described (Dahmane et al., 
2001). 
 
Prostate Tissue Microarrays and Microdissection 
After institutional review board approval, tissue microarrays (Matysiak et al., 
2003) were prepared from archived paraffin blocks from 288 radical prostatectomy cases 
from the Medical College of Wisconsin. For each case, 0.6-mm cores of tumor were 
isolated and placed in the array blocks, and 5-µm slides were prepared for 
immunohistochemistry. Slides were reviewed by a trained urologic pathologist 
(M.W.D.) and scored for the presence of benign prostate glands, high-grade prostatic 
intraepithelial neoplasia, or invasive tumor. The presence of tumor or high-grade 
prostatic intraepithelial neoplasia was confirmed by Immunohistochemical staining for 
high molecular mass cytokeratin (CK903 Ab, DAKO). Individual cores were examined 
as duplicates, and staining was correlated to a set of anonymous deidentified pathologic 
 120 
and outcomes data with χ2 and Fisher’s exact or two-tailed ANOVA analyses. 
Normal and tumor tissue from the same patients for real-time PCR analyses were 
microdissected from sections with a laser capture microscope after pathological 
assessment. 
 
SHH, Anti-SHH Antibody, Cyclopamine, and Tomatidine Treatments 
Commercial N-SHH (R & D Systems) was used at 100 nM because we have 
found that this commercial protein is ~20 times less active than the octyl-modified SHH-
N we had previously used from Curis in the C3H10T1/2 induction assay (data not 
shown). 5E1 anti-SHH blocking antibody (Ericson et al., 1996) was purchased from the 
Hybridoma Bank at the University of Iowa and was used at 8 µg/ml. Cyclopamine 
(Toronto Research Chemicals) and Tomatidine (Sigma) were used at 10 µM unless 
otherwise noted; for cells in culture, they were dissolved in ethanol, and ethanol alone 
was used as control. Treated cells were in 2.5% serum for 48 h instead of the usual 10% 
routinely used for standard growth. 
 
Proliferation Assays 
BrdUrd (Sigma) was given at 4 µg/ml before fixation. The time of the BrdUrd 
pulse depended on the growth rate of the cells tested. Cell lines were given a 2-h pulse, 
whereas primary tumor cultures, which grow less rapidly, were given 16-h pulses. 
Proliferation in tissue arrays was measured by the level of Ki-67 antigen expression. 
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PCRs 
For RT-PCRs, the following primers were used (all 5´ to 3´). GLI1s, 
GGGATGATCCCACATCCTCAGTC, and GLI1a, CTGGAGCAGCCCCCCCAGT at 
60°C; PSAs, CTTGTAGCCTCTCGTGGCAG, and PSAa, 
GACCTTCATAGCATCCGTGAG at 56°C. Primers for PTCH1 and GAPDH were as 
described (Dahmane et al., 2001; Palma and Ruiz i Altaba, 2004).  
For real-time PCR, total RNA was DNase treated (Invitrogen) and reverse 
transcribed with TaqMan (Applied Biosystems) using oligo(dT) primers as described by 
the manufacturer. Reactions were run by using SYBR Green (Applied Biosystems) on an 
ABI Prism 7700 machine. Each sample was run minimally at three concentrations in 
triplicate. All primer sets amplified 75- to 300-bp fragments. Sequences are available 
upon request. The raw data are available upon request from S.D. 
 
RNA Interference 
Double-stranded small interference RNAs (siRNAs, 21 nt long) were purchased 
from Dahrmacon, purified, and desalted. The sequences for the GLI1 siRNAs used was: 
AACUCCACAGGCAUACAGGAU; control siRNA was: 
AACGUACGCGGAAUACAACGA. This siRNA was also used FITCtagged. siRNA 
transfections (0.2 µM) were with Oligofectamine (Invitrogen) as described by the 
manufacturer. Cells were treated for 60 h before fixation. 
 
RESULTS 
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To begin to analyze the role of SHH-GLI signaling in prostate cancer, we first 
tested for the expression of SHH-GLI pathway components in prostate cancer resections 
and normal tissue from the same patients. In situ hybridization showed that GLI1, 
PTCH1, and SHH are normally coexpressed in epithelial cells and not in the surrounding 
stroma (Figure A-1 A, C, E, G, I, L, and O). Prostate tumors were uniformly 
SHH+/GLI1+/PTCH1+ (Figure A-1 B, D, F, H, J, K, M, N, P, and Q), although variable 
levels of expression were detected visually in the tumors. Coexpression of these markers 
in tumor cells is consistent with their derivation from the normal prostatic epithelium.  
More sensitive real-time PCR analyses of six of the same microdissected 
matched pairs showed up-regulation of the expression of SHH, PTCH1, GLI1, GLI2, and 
GLI3 (between 1.5- and ~300- fold) in many tumor cases compared to normal tissue 
after normalization to the ubiquitous similar expression of β-actin (Table A-1). Levels of 
expression within tumors were variable. Such differences could be related to the known 
heterogeneity of prostate cancer, because this is a general diagnosis that encompasses a 
broad range of histological phenotypes (Bostwick et al., 2004; DeMarzo et al., 2003; 
Kaplan-Lefko et al., 2003). Whereas varying levels have also been observed in other 
tumors (Ingham and McMahon, 2001; Ruiz i Altaba et al., 2002), the meaning of such 
differences is not known, although they have been proposed to correlate in a direct or 
inverse manner with tumor type or grade (Grachtchouk et al., 2003; Katayam et al., 
2002; Pomeroy et al., 2002). What is important is that the loyal markers of an active  
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Figure A-1. Expression of SHH–GLI pathway components in normal prostate 
tissue and prostate tumors. Sections of normal prostate tissue (A, C, E, G, I, L, and O) 
and prostate tumors (B, D, F, H, J, K, M, N, P, and Q) show hematoxylin and eosin (H & 
E) staining (A and B) or the expression of SHH (C, D, and I-K), PTCH1 (E, F, and L-N), 
and GLI1 (G,H, and O-Q). (GInset) Sense GLI1 probe control showing no background. 
Prostate tumors havemanysmall epithelial glandular structures. Black arrows point to 
expressing cells. White arrows point to nonexpressing cells. (R-T) Sections from the 
tissue microarrays of normal prostate tissue (R) and prostate tumors (S and T) showing 
expression of SHH protein with an anti-SHH antibody (αSHH Ab) (R-T) and a no 
primary antibody control (T Inset). All sections were counterstained with hematoxylin to 
visualize nuclei and tissue structure. Arrow in T points to localization of SHH protein in 
the cytoplasm of epithelial cells. e, epithelium; l, lumen; s, stroma; t, tumor. (Scale bar in 
T is 150 µm in A-H, R, and S, 20 µm in J, M, P, and T, and 10 µm in I-L, N, O, and Q.) 
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Table A-1. SHH, GLI1, GLI2, GLI3, and PTCH1 expression in human prostate 
cancer. 
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SHH-GLI pathway, GLI1 and (Goodrich et al., 1996; Lee et al., 1997; Podlasek et al., 
1999), are consistently transcribed in the examined tumor cells, showing the presence of 
an active pathway. 
To extend these findings, we performed immunohistochemistry for SHH, as a 
secreted and potentially useful systemic marker for prostate cancer, on tissue 
microarrays representing 239 prostate carcinomas, 15 precancerous lesion high-grade 
prostatic intraepithelial neoplasia (HGPIN), and 135 benign prostate tissues from 297 
patients. SHH expression was increased in tumors and was present as a secreted protein 
in the glandular lumens made by tumor cells (Figure A-1 R-T), likely reflecting the 
origin of tumors from the SHH+ prostatic epithelia. Higher SHH levels, determined 
visually, were found in 33% of tumors compared to <1% of cases of normal adjacent 
tissue, indicating a significant correlation between high SHH levels and tumor presence. 
High SHH levels were also correlated with higher Ki-67+ cell proliferation (Table A-2). 
The level of SHH expression was not correlated with Gleason score or other clinical 
parameters (Table A-2). This finding may indicate that inappropriately maintained or 
elevated SHH expression is an early and general event in prostate cancer, reflecting the 
origin of tumors from the SHH+ prostatic epithelia. 
The difficulty of growing human prostate cancer cells in vitro translates into a 
dearth of available cancer cells to test. Here we have chosen the three most widely used 
prostate cancer cell lines, LNCaP, an androgen sensitive cell line derived from a prostate 
cancer lymph node metastasis; and PC3 and DU145, androgen insensitive cell lines 
derived from prostate cancer bone metastases, to assay for the expression of SHH-GLI 
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Table A-2. Correlation of elevated SHH expression with tumorigenesis 
and clinical features of prostate cancer. 
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Figure A-2. Response of prostate tumor cell lines to alterations in the SHH-GLI 
pathway. (A) PCR analyses for the expression of SHH-GLI pathway components in 
three cell lines as indicated. In this and all other PCR assays, the expression of the 
ubiquitous gene GAPDH is measured as quantitative control. (B) Inhibition of prostate 
cell line proliferation as measured by BrdUrd incorporation in the three prostate cell 
lines used with cyclopamine. Tomatidine is used as control. (C and D) PCR analyses of 
the suppression of GLI1 expression in LNCaP cells by cyclopamine treatment at 36 h 
(C) or of the expression of prostate specific antigen (PSA), GLI1, SHH, and PTCH1 
expression in whole prostate tumor tissue (T), primary culture (C), the glioblastoma cell 
line U87 (U), and LNCaP (L) cells (D). PSA is expressed in prostate but not in brain 
cells. All samples express GLI1 and SHH. The whole tissue and primary culture 
correspond to PT6. (E) Histogram of the inhibition of BrdUrd incorporation in primary 
cultures of prostate tumor (PT3-PT8) by cyclopamine treatment. (F-I) 
Immunocytochemistry for BrdUrd incorporation with secondary FITC antibodies 
showing BrdUrd+ nuclei (green) in a field of primary prostate cells (PT6) in control cells 
(treated with ethanol as the carrier for cyclopamine, F), cyclopamine (G), SHH protein 
(H), or anti-SHH antibody (αSHH Ab, I). All nuclei are stained with 4′, 6-diamidino-2-
phenylindole (blue). (J and K) Histograms of the increase in (J) or inhibition of (K) 
BrdUrd incorporation of primary prostate tumors after treatment with SHH (J) or anti-
SHH antibody (αSHH Ab, K) for 48 h. Histogram error bars represent SEM in all 
panels.  
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Figure A-2 continued.  
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pathway components. All of the cells expressed GLI1 and PTCH1 (Figure A-2A), 
consistent with our expression studies and indicating that they harbor an active pathway. 
Of these cell lines, only DU145 and PC3 cells expressed GLI2, and only LNCaP and 
PC3 cells expressed GLI3 and SHH at detectable levels (Figure A-2A). GLI1 is thus the 
only GLI gene consistently expressed at detectable levels in all of these cells, and thus, 
we have focused on GLI1. 
To interfere with SHH-GLI signaling, we first used cyclopamine, a selective 
inhibitor of SMOH (Chen et al., 2002). Effects of cyclopamine treatment after 48 h were 
tested by BrdUrd incorporation as a sensitive measure of cell proliferation. Such 
treatment led to a large (>80%) decrease in BrdUrd incorporation in LNCaP cells, and a 
significant decrease (≈30%) in PC3 cells but had no effect in DU145 cells (Figure A-
2B). Treatment with tomatidine (Chen et al., 2002)served as control and had little or no 
effect on BrdUrd incorporation (Figure A-2B). The lack of effects of cyclopamine on 
DU145 cells shows that this drug is not nonspecific. Because we used short-term assays 
to focus on early, direct effects on cell proliferation, the changes in total cell number 
were consequently relatively conservative. For instance, cyclopamine reduced total 4′, 6-
diamidino-2-phenylindole-positive LNCaP cell number by 22.1±1.1% (P=0.0001) after 
48 h. No cytotoxic effects or significant cell death were observed during these 
experiments. Cyclopamine treatment also led to a decrease in GLI1 expression, 
consistent with the expected down-regulation of the SHH-GLI pathway (Figure A-2C). 
Analyses of primary prostate tumors is complicated by the difficulty of growing 
primary human prostate cancer cultures (Rhim, 2000). Nevertheless, we were able to 
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dissociate and plate six of eight primary prostate tumors, although stable cultures were 
not obtained. Primary cells that remained attached after 2 days had a uniformcuboidal 
morphology, formed small clusters and expressed prostate-specific antigen (PSA), as 
well as SHH, PTCH1, and GLI1 (Figure A-2D), proving their prostatic epithelial origin. 
Cyclopamine treatment led to a major (>70%) decrease in BrdUrd incorporation in all 
primary cultures as compared with carrier-treated samples (Figure A-2E-G), mimicking 
the results obtained in LNCaP cells. Here again, the insensitivity of DU145 to 
cyclopamine provides a control for the action of the drug. Indeed, although we have not 
tested the response of normal human prostate cells to cyclopamine, we expect that it 
would also inhibit the proliferation of normal SHH+/ PTCH1+/GLI1+ prostate epithelial 
cells (Figure A-1). As with the cell lines, the total number of 4′, 6-diamidino-2-
phenylindole-positive primary tumor cells was similarly reduced by cyclopamine 
treatment [e.g., 26.7 ± 1.1% decrease in primary tumor 6 (PT6), P = 0.001] after 48 h. 
Although stromal cells are likely to be present in our primary cultures, their numbers 
appear to be small because >90% of the cells examined microscopically had a similar 
cuboidal morphology. Moreover, the high inhibition levels by cyclopamine would be 
inconsistent with effects only in contaminating stromal cells, which do not appreciably 
express PTCH1 or GLI1 (Figure A-1). 
We then tested for the ability of exogenous SHH to stimulate prostate cancer cell 
proliferation and for the possible existence of autocrine signaling. Addition of 
recombinant SHH protein led to an increase in BrdUrd incorporation in two of four 
primary cultures after 48 h (Figure A-2F, H, and J). In contrast, addition of the standard 
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blocking antibody against SHH (5E1; (Ericson et al., 1996)) resulted in an inhibition of 
BrdUrd incorporation by 15-40% for three of four tumors (Figure A-2F, I, and K), 
suggesting that several tumors display autocrine signaling. Interestingly, the only 
primary culture that was insensitive to Shh Ab blockade, PT7, being sensitive to 
cyclopamine [which targets SMOH (Chen et al., 2002), Figure 2E], was also the more 
sensitive to the addition of exogenous Shh. This might indicate that although the 
pathway is activated downstream of the site of ligand action in PT7, possibly affecting 
PTCH1 or SMOH, exogenous Shh can still increase the levels of signaling. Taken 
together, the functional heterogeneity that we detect parallels that found for GLI and 
SHH expression described above and may reflect independent activating events as well 
as the well known heterogeneity of prostate cancers. 
Treatment of LNCaP, PC3 or DU145 cells with either blocking antibody 
recombinant Shh protein did not result in significant changes in BrdUrd incorporation 
(data not shown). LNCaP and PC3 cells could thus display an activated pathway at the 
membrane level (being sensitive to cyclopamine inhibition) that has lost responsiveness 
to ligand. Cyclopamine-insensitive DU145 cells may have an activated pathway 
downstream of SMOH (or at the level of SMOH affecting its inhibition by 
cyclopamine), having lost also the ability to respond to SHH. It remains possible that the 
different behavior of primary cultures versus established cell lines also reflects unrelated 
transformation or immortalization events.  
The GLI zinc-finger transcription factors have been suggested to be essential for 
the mediation of HH signals (Ingham and McMahon, 2001; Ruiz i Altaba et al., 2002; 
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Ruiz i Altaba et al., 2004). However, Gli1 is apparently redundant in mouse 
development and tumorigenesis (Park et al., 2000; Weiner et al., 2002), and there is to 
date no data on the requirement for GLI1 in human cells. Here, we tested the function of 
GLI1, the only GLI gene consistently expressed in all primary tumors and cell lines, by 
RNA interference to knockdown its function with a specific 21-nt-long small RNA. 
(This siRNA inhibits the effect of SHH on multipotent C3H10T1/2 cells; P.S. and 
A.R.A., unpublished data). Lipofection of primary cultures resulted in a negligible 
number of transfected cells, making it impractical to use siRNAs in such cultures. In 
contrast, lipofection of FITC-siRNA proved efficient (≈50-80%) in the LNCaP, PC3, 
and DU145 cell lines (Figure A-3A-C). It is important to note that, because transfection 
efficiencies are <100%, the results of cell pool assays necessarily underestimate the 
effects of RNA interference. Transfection of a control siRNA at the same concentration 
served as control in all tests. 
The specificity of the GLI1 siRNA was further tested in LNCaP cells. Reduction 
of GLI1 mRNA levels by the GLI1 siRNA was detected as early as 3 h after transfection 
and at 8 and 24 h, but not at 48 h (Figure A-3 D and F and data not shown), suggesting 
upregulation of GLI1 after its inhibition, possibly because of the action of a rapid 
positive feedback loop (Dahmane et al., 2001; Regl et al., 2002). GLI1 siRNA also 
robustly repressed PTCH1, a result most clearly seen at 48 h, but not the housekeeping 
gene GAPDH (Figure A-3D and data not shown). Because PTCH1 is a SHH target 
(Goodrich et al., 1996), and in particular of GLI1 (Agren et al., 2004), this result 
indicates that interference with GLI1 function by RNAi is selective and effective in 
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Figure A-3.  Response of prostate cell lines to GLI1 RNA interference.  (A-C) 
Immunocytochemisty of the three prostate cell lines indicated showing the efficiency of 
lipofection of an FITC-tagged control siRNA (green). Note the lower efficiency in PC3 
cells. (D) Effect of GLI1 siRNA on gene expression. RNA interference reduces GLI1 
and PTCH1 mRNA levels as seen at 24 and 48 h, respectively (E) Histogram of the 
inhibition of BrdUrd incorporation in prostate tumor cell lines by GLI1 siRNA. (F) 
Specificity of the effects of GLI1 siRNA on GLI1 mRNA levels in the three prostate cell 
lines, compared with those of a control unrelated siRNA, 8 h after transfection. The 
levels of GAPDH are shown below as controls. 
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prostate cancer cells. GLI1 siRNA also decreased GLI1 mRNA levels in DU145 and 
PC3 cells after 8 h (Figure A-3F). 
Inhibition of GLI1 by RNA interference led to a variable reduction in BrdUrd 
incorporation in all three cell lines, with strongest effects (≈60%) in LNCaP cells (Figure 
A-3E). These cells are thus very sensitive to inhibition by cyclopamine and 
GLI1interference, suggesting the presence of a fully active canonical pathway activated 
at the level of SMOH or upstream, but downstream of SHH, because treatment with the 
blocking anti-SHH Ab had no effect. DU145 cells are not sensitive to cyclopamine, but 
are sensitive to GLI1 interference, suggesting activation downstream of SMOH and 
upstream or at the level of GLI1 function. In contrast, PC3 cells are sensitive to 
cyclopamine and less so to GLI1 interference, perhaps suggesting compensation by the 
other GLI proteins because PC3 cells express GLI2 [and this GLI gene mediates SHH 
signals (Roessler et al., 2003) and can behave like Gli1 in mice (Bai and Joyner, 2001)] 
or the presence of alternate pathways for tumor cell proliferation. We note, however, that 
lipofection efficiencies in PC3 cells (Figure A-3C) are the lowest (≈50%) of the three 
cells tested, indicating that the real effects of GLI1 interference may be higher. Taken 
together, our results show the requirement of GLI1 in human prostate tumor cells. 
 
DISCUSSION 
Here we demonstrate the dependence of prostate cancer cell proliferation on 
SHH-GLI pathway activity. The data suggest activation of the pathway at different 
levels in primary prostate tumors and cell lines derived from metastatic lesions. These 
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findings, together with the involvement of this pathway in normal prostate development 
and growth (Barnett et al., 2002; Berman et al., 2004; Freestone et al., 2003; Lamm et 
al., 2002; Podlasek et al., 1999; Wang et al., 2003), indicate that the normal patterning 
role of SHH-GLI signaling is deregulated in cancer. This idea is consistent with the 
proposed events in other tissues, including brain, lung, stomach, muscle, pancreas, and 
skin, in which the SHH-GLI pathway regulates patterned growth and when deregulated 
can give rise to SHH-GLI dependent tumors (Barnett et al., 2002; Berman et al., 2004; 
Freestone et al., 2003; Lamm et al., 2002; Pasca di Magliano and Hebrok, 2003; 
Podlasek et al., 1999; Ruiz i Altaba et al., 2002; Wang et al., 2003). Thus, there is a 
surprising and unexpected parallel in the requirement of SHH-GLI signaling of prostate 
tumors with those in organs of very different origin, function, and location. 
The deduction that prostate tumors display activation at different levels is 
consistent with findings in brain ((Dahmane et al., 2001)and P.S. and A.R.A., 
unpublished data) and pancreatic (Nelson et al., 2003) tumors, even though the entire set 
of activating events or mutations have not been described in any case. Indeed, our data 
suggest that the regulation of the SHH-GLI pathway in the normal prostatic epithelium is 
altered away from homeostasis in the tumors by epigenetic events or mutations in 
components such as PTCH1, SMOH, or SUFUH, similar to those already found in other 
tumors (e.g., (Dong et al., 2000; Pietsch et al., 1997; Raffel et al., 1997; Reifenberger et 
al., 1998; Taylor et al., 2002; Wolter et al., 1997; Zurawel et al., 2000)). However, the 
finding that the pathway is active as assessed by the expression of GLI1 and PTCH1 [as 
in the case of basal cell carcinomas (Dahmane et al., 1997), medulloblastomas 
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(Dahmane et al., 2001)and gliomas (Dahmane et al., 2001)] allows us to bypass the 
identification of the likely myriad of activating events to discern that tumor cells harbor 
an active pathway. Indeed, the finding that SHH expression levels are not correlated with 
Gleason score, but that all prostate tumor samples tested require continued pathway 
activity for proliferation, allows us to propose that this pathway is a critical and essential 
component of prostate cancer. 
Specifically, we show the requirement for SHH, SMOH, and/or GLI1 for the 
proliferation of prostate cancer cells. The fact that all primary tumors tested are sensitive 
to cyclopamine indicates that SMOH, or upstream elements from it, are common targets 
leading to the activation of downstream mediators. Several primary cultures are also 
sensitive to inhibition by blocking anti-SHH Ab, suggesting that, like in stomach tumors 
(Berman et al., 2003), autocrine signaling is a frequent cause of pathway activation in 
prostate cancer. The consistent expression of GLI1 in tumor cell lines and in primary 
tumors together with the effects of RNA interference indicate that this GLI gene plays a 
central and general role in prostate tumor cell proliferation, and demonstrate its 
requirement in human tumorigenesis. In contrast, GLI2 and GLI3 do not appear to be 
consistently expressed in prostate cancer cells. When expressed, they could have 
complementary or compensatory roles in some cases, although their roles remain to be 
determined. 
Prostate cancer is thought to develop from a lesion in the epithelial layer to 
become an invasive tumor that spreads within the prostate and subsequently acquires the 
potential to metastasize to distant sites, most often the lymph nodes and bone (Abate-
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Shen and Shen, 2000). Inhibition of testosterone-dependent tumor growth is the common 
treatment for advanced disease, but subsequent hormone-independent cell proliferation 
and metastasis often leads to patient death (Martel et al., 2003). Our data on the behavior 
of the three prostate cancer cell lines derived from metastatic lesions suggest that such 
tumors could harbor additional changes that may make them ligand-independent, albeit 
still being SHH-GLI pathway dependent, and explain their differential behavior in 
comparison with the primary cultures. Perhaps the gain of intracellular, cell-autonomous 
activation of the SHH-GLI pathway represents an advantage for metastatic cells, 
allowing efficient proliferation far from the prostatic epithelium, where SHH appears to 
be continually and abundantly produced. 
The high inhibition of proliferation by SHH-GLI pathway blockade of the 
presumed androgen-sensitive primary tumors used in this study, which derive from 
patients that did not receive hormone treatments, and of the androgen sensitive LNCaP 
cell line might be related to the proposed requirement of Shh signaling for normal 
androgen function, because defects derived from loss of Shh signaling in mice can be 
rescued by exogenous androgens (Berman et al., 2004). Prostate cancer could therefore 
initiate through inappropriate maintenance or enhanced activity of SHH-GLI signaling, 
and more aggressive (androgen insensitive) states may require additional alterations. 
Nevertheless, the inhibition of the androgen-insensitive DU145 cell line by RNA 
interference suggests that even highly aggressive tumors may be sensitive, albeit to 
different degrees, to GLI1 inhibition. 
Prostate stem cells may play a critical role in the epithelial development and 
 138 
homeostasis (Bonkhoff, 1996; De Marzo et al., 1998). Because cancer may be a disease 
of stem cell lineages (discussed in (Pasca di Magliano and Hebrok, 2003; Reya et al., 
2001; Ruiz i Altaba et al., 2002; Ruiz i Altaba et al., 2004)) and SHH-GLI signaling 
controls the behavior of precursors and of cells with stem cell properties in the 
mammalian brain (e.g., (Lai et al., 2003; Machold et al., 2003; Palma and Ruiz i Altaba, 
2004)and V. Palma, D. Lim, N. Dahmane, N., P.S., Y. Gitton, A. Alvarez-Buylla, A., 
and A.R.A., unpublished data) and in other tissues and species (Park et al., 2003b; Zhang 
and Kalderon, 2001)), prostate cancer might derive from inappropriate expansion of 
prostatic epithelial stem cell lineages caused by abnormal SHH-GLI function. 
Finally, our data suggest that SHH and GLI1 may not only be useful markers for 
prostate cancer but also good targets for anticancer therapies, with emphasis on GLI 
function as the last and essential step of the pathway, the inhibition of which will likely 
block signaling by upstream events at any level. SHH-GLI pathway blocking agents 
should thus provide attractive therapeutic strategies to combat prostate cancer of any 
grade. 
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APPENDIX B 
Perlecan, A CANDIDATE GENE FOR THE CAPB LOCUS, 
REGULATES PROSTATE CANCER CELL GROWTH VIA THE 
SONIC HEDGEHOG PATHWAY* 
CONTRIBUTIONS 
My contribution to the work in (Datta et al., 2006a) involved analysis of the 
effects PERLECAN has on SHH signaling in an established prostate cancer cell line 
series.   I assisted Ana Maria Hernandez, a graduate student in Dr. Datta’s lab, by 
performing several qRT-PCR experiments on PERLECAN RNAi treated LNCaP cells, 
which are the least invasive/most androgen sensitive cells in the prostate cancer cell line 
series.  Results of this experiment showed a decrease in expression of PTCH1 and GLI1 
(80% and 90% decrease, respectively), transcriptional targets of the SHH-GLI signaling 
pathway, compared to non-RNAi treated controls (Figure B-4A).  This suggests that 
PERLECAN is a key modulator of SHH signaling in prostate cancer cells. 
 
ABSTRACT 
Genetic studies associated the CAPB locus with familial risk of brain and 
prostate cancers. We have identified HSPG2 (Perlecan) as a candidate gene for CAPB.  
___________ 
*Reprinted with permission from Datta, M.W., Hernandez, A.M., Schlicht, M.J., Kahler, 
A.J., DeGueme, A.M., Dhir, R., Shah, R.B., Farach-Carson, C., Barrett, A., and Datta, S. 
2006. Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell 
growth via the Sonic Hedgehog pathway.  Mol Cancer 5, 9.  Copyright 2006 © by 
BioMed Central Ltd. 
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Previously we have linked Perlecan to Hedgehog signaling in Drosophila. More 
recently, we have demonstrated the importance of Hedgehog signaling in humans for 
advanced prostate cancer. Here we demonstrate Perlecan expression in prostate cancer, 
and its function in prostate cancer cell growth through interaction and modulation of 
Sonic Hedgehog (SHH) signaling. Perlecan expression in prostate cancer tissues 
correlates with a high Gleason score and rapid cell proliferation. Perlecan is highly 
expressed in prostate cancer cell lines, including androgen insensitive cell lines and cell 
lines selected for metastatic properties. Inhibition of Perlecan expression in these cell 
lines decreases cell growth. Simultaneous blockade of Perlecan expression and androgen 
signaling in the androgen-sensitive cell line LNCaP was additive, indicating the 
independence of these two pathways. Perlecan expression correlates with SHH in tumor 
tissue microarrays and increased tumor cell proliferation based on Ki-67 
immunohistochemistry. Inhibition of Perlecan expression by siRNA in prostate cancer 
cell lines decreases SHH signaling while expression of the downstream SHH effector 
GLI1 rescues the proliferation defect. Perlecan forms complexes with increasing 
amounts of SHH that correlate with increasing metastatic potential of the prostate cancer 
cell line. SHH signaling also increases in the more metastatic cell lines. Metastatic 
prostate cancer cell lines grown under serum-starved conditions (low androgen and 
growth factors) resulted in maintenance of Perlecan expression. Under low androgen, 
low growth factor conditions, Perlecan expression level correlates with the ability of the 
cells to maintain SHH signaling. We have demonstrated that Perlecan, a candidate gene 
for the CAPB locus, is a new component of the SHH pathway in prostate tumors and 
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works independently of androgen signaling. In metastatic tumor cells increased SHH 
signaling correlates with the maintenance of Perlecan expression and more Perlecan-
SHH complexes. Perlecan is a proteoglycan that regulates extracellular and stromal 
accessibility to growth factors such as SHH, thus allowing for the maintenance of SHH 
signaling under growth factor limiting conditions. This proteoglycan represents an 
important central regulator of SHH activity and presents an ideal drug target for blocking 
SHH effects. 
 
BACKGROUND 
Genetic mapping studies for familial prostate cancer have identified numerous 
chromosomal regions linked to prostate cancer susceptibility. On chromosome one a 
genetic association has been demonstrated between clinically significant prostate cancer 
and the brain tumor glioblastoma multiforme at 1p36 (CArcinoma Prostate Brain, 
CAPB), suggesting the presence of a common oncogene for these tumors (Conlon et al., 
2003; Gibbs et al., 1999; Janer et al., 2003; Park et al., 2003b; Zhang and Kalderon, 
2001). Using bioinformatics based analysis of text mining and gene expression data we 
have identified candidate genes within the CAPB locus. One of these genes is HSPG2 
(Perlecan). Perlecan is a heparan sulfate proteoglycan that is secreted into the 
extracellular matrix and can bind growth factors (Iozzo et al., 1994). Thus Perlecan can 
act as a reservoir or modulator of growth factor function.  One growth factor associated 
with Perlecan is Hedgehog (Park et al., 2003b). Sonic Hedgehog signaling has recently 
been shown to be critical for cancer growth and metastasis in multiple tumor types 
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(Datta and Datta, 2006)In a large proportion of prostate cancers high levels of Sonic 
Hedgehog expression is observed along with expression of multiple members of the 
Hedgehog signaling pathway such as its receptor Patched1, downstream transcription 
factor Gli1, and intracellular modulator Hedgehog Interacting Protein (Sanchez et al., 
2004; Sheng et al., 2004). Activation of the Hedgehog pathway has been detected in 
metastatic prostate tumors (Karhadkar et al., 2004; Sheng et al., 2004), and higher levels 
of pathway activity are associated with the metastatic phenotype (Karhadkar et al., 
2004). Blocking the Sonic Hedgehog pathway with cyclopamine inhibits proliferation of 
prostate cancer cell lines (Karhadkar et al., 2004; Sanchez et al., 2004; Sheng et al., 
2004) and primary prostate tumor cell cultures (Sanchez et al., 2004). Treatment of mice 
with cyclopamine results in the inhibition of tumor xenograft growth in multiple tumor 
types, including prostate tumors (Berman et al., 2003; Sanchez et al., 2004). Our 
bioinformatics analyses (Datta and Datta, 2006; Sanchez et al., 2004) suggested that 
genes encoding two components of the Sonic Hedgehog pathway, Suppressor of Fused 
(Su(fu)) and Smoothened, the target of cyclopamine, lie in chromosomal regions 
implicated in familial prostate cancer (Easton et al., 2003; Xu et al., 2003). Su(fu) is a 
negative regulator of pathway activity, thus loss of Su(fu) function would increase Sonic 
Hedgehog activity. Molecular analyses of prostate tumors revealed that Su(fu) protein is 
absent in most highly aggressive tumors and somatic truncation mutations in the Su(fu) 
gene have been identified (Sheng et al., 2004) consistent with the hypothesis that Su(fu) 
would act as a prostate tumor suppressor gene by inhibiting Sonic Hedgehog signaling. 
These studies demonstrate the critical nature of Sonic Hedgehog signaling in 
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tumorigenesis and metastasis. Thus identification of additional mechanisms for the 
regulation of Sonic Hedgehog signaling in cancer takes on added importance. Here we 
demonstrate that expression of the candidate CAPB gene HSPG2 (Perlecan) is present 
in prostate cancers, up-regulated in aggressive prostate cancers and under poor cell 
growth conditions, and regulates prostate cancer cell proliferation. In addition, we 
demonstrate that Perlecan's effects on cell growth are independent of androgen signaling 
and occur through the binding of Sonic Hedgehog, resulting in modulation of the Sonic 
Hedgehog-Patched-Gli signaling pathway. This data, along with data linking Perlecan to 
metastatic tumor environments such a bone matrix (Savore et al., 2005), presents a 
general model in which Perlecan expression by tumor cells under poor growth 
conditions enhances their ability to utilize growth factors until their spread to suitable 
metastatic tumor microenvironments for accelerated growth. 
 
RESULTS 
Perlecan is expressed in and associated with aggressive prostate cancers 
After identification of Perlecan as a candidate gene for the CAPB locus we 
sought to confirm the presence of Perlecan in primary prostate cancers. 
Immunohistochemical analysis for Perlecan in prostate cancer tissue microarrays with 
600 patient samples demonstrated that Perlecan, a secreted proteoglycan, is present in 
the lumens of 54% of malignant prostate cancer glands, but not in normal glands (Figure 
B-1A–D, Table B-1). There was a significant increase in Perlecan levels in invasive 
tumors compared to either benign prostate tissue or the precancerous lesion high grade 
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Figure B-1.  Perlecan protein levels in human prostate tumors.  
Immunohistochemistry of Perlecan protein in prostate cancer (A) and normal prostate 
(B). Perlecan is present as a secreted protein in the tumor gland lumens (C) but not in the 
lumens of benign glands or benign corpora amylacea secretions (D). Staining is also 
seen in metastatic prostate cancer specimens (E). Secondary antibody alone control fails 
to demonstrate staining (F). All images originally photographed at 400 X magnification. 
Quantitation of Perlecan mRNA expression by Real Time PCR (G) or protein by 
digitized dot blot (H) in normal prostate and tumor samples from individual patients 
presented as fold change in tumor versus normal. Gleason scores for the tumors are 
listed. Red numbers or columns indicate patients previously shown to have increased 
expression of SHH, PTCH1 and GLI1 (Dahmane et al., 2001). 
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Table B-1. Immunohistochemical staining for Perlecan and co-localization with Ki-67. 
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prostatic intraepithelial neoplasia (HGPIN). In particular Perlecan expression was 
associated with more aggressive tumors, as evidenced by their higher Gleason score 
(Gleason score 7,8,9 versus Gleason score 5 and 6 tumors). Perlecan expression was  
also significantly associated with increased prostate cancer cell proliferation, as 
demonstrated by Ki-67 (PCNA) Immunohistochemical staining (Table B-1). To extend 
the evaluation of Perlecan we examined Perlecan RNA (Figure B-1G) and/or protein 
(Figure B-1H) levels in matched benign and tumor samples from 10 individual patients. 
At the RNA level Perlecan was significantly increased in four out of six matched patient 
tumor and benign prostate samples. Perlecan protein was upregulated in two of four 
additional patient samples where protein was examined. An examination of the Gleason 
score for the primary tumor samples revealed that the only Gleason score 8 tumor 
upregulated Perlecan. These findings correlate with the results from the tissue 
microarrays (Table B-1). Perlecan Ki-67 staining was also evaluated in five of the 
patient samples, two with low Perlecan, and three with increased Perlecan expression. 
Immunoblotting demonstrated a direct correlation between increased Perlecan 
expression and increased Ki- 67 levels. These findings matched the 
Immunohistochemical staining results from the tissue microarrays (Table B-1). We also 
examined Perlecan protein expression on tissue microarray samples from patients with 
primary and metastatic prostate cancer identified at autopsy. In these samples Perlecan 
expression was upregulated in the primary prostate tumor and metastatic prostate cancer 
that had spread to the lungs and liver (Figure B-1E, Table B-1). Perlecan expression was 
lower in tumor present in lymph nodes or soft tissue metastasis, indicating site-specific 
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differences in Perlecan expression in metastatic prostate cancer. 
 
Basal Perlecan expression is highest in an androgen sensitive tumor cell line 
Baseline expression of Perlecan was examined in the metastatic prostate cancer 
cell lines LNCaP, DU-145, and PC3. Using analysis of spotted cDNA microarray 
expression data (Schlicht et al., 2004) quantitative Real Time PCR and immunoblotting, 
Perlecan expression was found in all three cell lines with the highest levels present in 
the androgen sensitive LNCaP cell line (Figure B-2A). We extended these findings by 
examining Perlecan expression with respect to tumor cell invasion and metastasis in an 
LNCaP tumor progression model. The LNCaP-derived cell line series (LNCaP, C4, C4-
2, C4-2B) were derived from serial passage through nude mice (Thalmann et al., 2000; 
Wu et al., 1994). The androgen sensitive parental LNCaP line is incapable of forming 
tumors in nude mice without stromal cell support. The C4 subline will form tumors 
when injected into castrated males, indicating that it is androgen insensitive, but will not 
metastasize. C4-2 is an androgen insensitive line that will metastasize, and the C4-2B 
subline is an androgen insensitive line that rapidly forms bone metastases. When 
Perlecan expression was assayed in the LNCaP series (Figure B-2A) Perlecan RNA and 
protein was present in all the prostate cancer cell lines at levels lower than the androgen 
sensitive LNCaP cells. Thus all the androgen insensitive prostate cancer cell lines 
expressed lower levels of Perlecan RNA than he androgen sensitive cell line. 
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Figure B-2.  Perlecan expression and functional analysis in cell lines. A. Relative 
Perlecan mRNA levels from Realtime PCR (LNCaP series) and spotted cDNA 
microarray data (LNCaP, DU145, PC3). All samples presented normalized to LNCaP at 
100%. Androgen sensitive: LNCaP. Androgen insensitive: C4, C4-2, C4-2B, PC3, 
DU145. B. Inhibition by Perlecan siRNA decreases prostate cancer cell proliferation. 
BrdU incorporation in the LNCaP, C4, C4-2 and C4-2B cell lines. All samples were 
normalized to control (scrambled siRNA treated) cells at 100%. Black bars represent 
control samples transfected with scrambled siRNA. Grey bars represent samples 
transfected with Perlecan siRNA. Error bars represent n = 3 independent samples. C. 
Additive effect of Perlecan siRNA and androgen blockade on cell proliferation. BrdU 
incorporation in LNCaP cells after Perlecan siRNA and/or bicalutimide (Casodex) 
treatment. Control and Casodex alone samples were treated with a scrambled siRNA. p < 
0.0001 for comparisons between groups. Error bars represent n = 6 for independent 
transfections. 
A 
B 
C 
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Inhibition of Perlecan decreases prostate cancer cell proliferation in androgen sensitive 
and androgen insensitive tumor cells 
To examine the direct effect of Perlecan on cancer cell growth we examined the  
ability of small interference RNA (siRNA) directed at Perlecan message to inhibit cell 
growth in the increasingly metastatic LNCaP cell line series LNCaP, C4, C4-2 and C4-
2B. Proliferation assays demonstrated approximately equal decreases in BrdU 
incorporation for each cell line (Figure B-2B). To evaluate the relationship between 
Perlecan and androgens on cancer cell growth we performed BrdU incorporation studies 
on the androgen sensitive LNCaP cells utilizing androgen blockade with bicalutimide 
(Casodex) with Perlecan siRNA or a scrambled siRNA control (Figure B-2C). 
Independent application of Perlecan siRNA or androgen blockade resulted in 28% and 
45% decreases in BrdU incorporation respectively. When combined, Perlecan siRNA 
and androgen blockade resulted in an additive effect with a 62% reduction. 
 
Perlecan correlates with Sonic Hedgehog expression 
Since androgen signaling and Perlecan effects on tumor cell proliferation are 
independent, we asked what other signaling pathway Perlecan might be modulating to 
support prostate cancer cell growth. Others and we have recently shown that Sonic 
Hedgehog regulates prostate cancer cell growth (Datta and Datta, 2006; Fan et al., 2004; 
Karhadkar et al., 2004; Sanchez et al., 2004; Sheng et al., 2004). Since Perlecan has been 
implicated in Hedgehog signaling in Drosophila (Park et al., 2003b), we examined the 
correlation and interaction of Perlecan with Sonic Hedgehog in prostate cancer samples.  
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Figure B-3.  Co-localization of Shh and Perlecan, and correlation with Ki-67 
staining.  Immunohistochemistry for Sonic Hedgehog (A), demonstrating both weak 
cytoplasmic staining in prostate cancer epithelial cells and stronger intraluminal staining 
of secreted SHH. Co-localization of Perlecan (B) and Sonic Hedgehog (C) in 
consecutive sections of prostate carcinoma. Examples of co-localization of the secreted 
proteins in gland lumens are highlighted (red asterisks). All histologic images originally 
photographed at 400 X magnification. Significant co-localization of Perlecan and SHH 
staining was associated with higher cellular proliferation rates as indicated by Ki-67 
nuclear staining by immunohistochemistry (D). 
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Using sequential slides from tissue microarrays we compared the staining patterns for 
Perlecan and Sonic Hedgehog (Figures B-3A–3C). Co-localization of Perlecan and 
Sonic Hedgehog staining was noted in a significant number of tumors, while luminal 
Sonic Hedgehog was not observed in normal prostate controls. In addition, co-
localization of both Perlecan and Sonic Hedgehog correlated with increased tumor cell 
proliferation as shown by Ki-67 (PCNA) staining (Figure B-3D). Our previous studies 
(Sanchez et al., 2004) had examined expression of SHH pathway genes in six matched 
benign and tumor patient samples where we have also examined Perlecan mRNA or 
protein expression (Figure B-1G, B-1H). In four common samples where we observe up-
regulation of Perlecan in tumor tissue, we previously detected up-regulation of SHH, 
PTCH1 and GLI1 (patients 945, 1854, 921 and 1866) suggesting a complete functional 
pathway in these tumors. In two common samples where we observe decreased Perlecan 
mRNA levels, we previously saw decreased SHH expression (patients 829 and 887). 
Thus in individual patients, tumor expression of Perlecan and SHH are correlated, in 
agreement with the co-localization of Perlecan and SHH in tissue microarrays. 
 
Inhibition of Perlecan blocks Sonic Hedgehog signaling in cancer cells 
To investigate whether Perlecan is directly involved in modulating SHH 
signaling we examined the effect of Perlecan siRNA on expression of PTCH1 and GLI1, 
transcriptional targets of the SHH-GLI pathway (Lee et al., 1997) in LNCaP cells. Real-
Time PCR analysis of Perlecan siRNA treated cells revealed the expected 80% decrease 
in Perlecan RNA, along with an 80% decrease in the level of PTCH1 expression and a 
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Figure B-4.  Perlecan and the SHH-GLI1 pathway. A. Decreased Perlecan and SHH 
signaling in Perlecan RNAi treated LNCaP cells. Expression of Perlecan, and the SHH 
signaling molecules PTCH1 and GLI1 as determined by Real Time PCR. Black columns 
represent control samples, Grey columns represent Perlecan RNAi treated cells. All 
expression normalized to β-actin levels. Real Time PCR studies were run with an n = 9. 
Error bars indicate standard deviation. B. Gli-1 transfection restores BrdU Proliferation 
in Perlecan RNAi treated cells. Percent BrdU incorporation normalized to levels of BrdU 
incorporation in control (scrambled RNAi treated) cells. BrdU analysis was done with n 
= 6. Error bars indicate standard deviation. C. Immunoprecipitation with anti-Perlecan 
antibody pulls down SHH. Co-immunoprecipitation of SHH and Perlecan from equal 
amounts of medium conditioned by 80% confluent cells. Size marker is indicated. Due 
to modifications, mature SHH runs as an approximately 22 kD band. Note the increased 
amount of bound SHH in the C4-2 and C4-2B cell lines. D. Relative expression of the 
SHH pathway components in LNCaP series cells. Black columns represent SHH mRNA, 
grey columns represent PTCH mRNA, with expression presented as ratios with respect 
to expression in LNCaP cells. While SHH is lower, PTCH is higher in the androgen 
insensitive metastatic cell lines C4-2 and C4-2B compared to LNCaP. All mRNAs by 
QRT-PCR were normalized to Beta-actin. 
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90% decrease in GLI1expression compared to controls (Figure B-4A). A similar 
decrease in Perlecan protein levels in Perlecan siRNA treated LNCaP cells compared to 
control siRNA was noted (data not shown). These results demonstrate that Perlecan is 
required in androgen sensitive prostate cancer cells to achieve maximal SHH signaling 
activity. Given that Perlecan has been shown to modulate the signaling of multiple 
growth factors including FGF2, FGF10 and VEGF, we asked if the reduction of prostate 
cancer cell growth in Perlecan siRNA treated cells was a result of decreased SHH 
signaling. If the decreased BrdU incorporation was due to inhibition of SHH signaling, 
then expression of the SHH downstream effector GLI1 should rescue the effects of 
Perlecan siRNA treatment. LNCaP cells were simultaneously transfected with Perlecan 
siRNA and an expression vector for GLI1 and their proliferation compared to that of 
controls transfected only with Perlecan siRNA (Figure B-4B). As we observed earlier, 
transfection of Perlecan siRNA alone resulted in a drop in BrdU incorporation compared 
to controls. When Perlecan RNAi and the GLI1 expression vector were co-transfected, 
the percentage of BrdU labeling returned to control levels. Transfection of the GLI1 
expression vector alone did not appreciably change LNCaP cell proliferation. This 
demonstrates that the major role of Perlecan in LNCaP cells is to maintain levels of SHH 
signaling. 
 
Perlecan forms a complex with Sonic Hedgehog 
Finally, we asked how Perlecan might affect signaling by SHH. Previously, we 
had demonstrated that Perlecan from flies or mice forms a complex with Hedgehog 
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(Park et al., 2003b). To test for a tumor cell complex containing both Perlecan and SHH 
we performed co immunoprecipitation studies from the LNCaP series (Figure B-4C). 
Perlecan-SHH complexes were detected in the conditioned medium of all cell lines 
under normal growth conditions. The mature Sonic Hedgehog protein was identified by 
Western blotting in all protein extracts precipitated with anti-Perlecan antibodies but not 
from extracts precipitated with control antibodies. Increased amounts of SHH-Perlecan 
complexes were detected in C4-2 and C4-2B, the two metastatic cell lines. The level of 
Perlecan protein does not change appreciably in the LNCaP series (Figure B-5B), while 
the levels of SHH mRNA decrease across the series with increasing metastatic potential 
(Figure B-4D). The presence of higher levels of SHH bound to Perlecan in the C4-2 and 
C4-2B cells when the levels of Perlecan protein are similar across the cell lines suggests 
increased binding of SHH to the available Perlecan. The increased amount of bound 
SHH is apparently functional, as Real-Time PCR studies indicate a relative increase in 
PTCH1 expression with respect to SHH in C4-2 and C4-2B when compared to LNCaP 
(Figure B-4D). Taken together, the results of our expression, inhibition, and biochemical 
studies link Perlecan expression and function to SHH-GLI pathway activity in advanced 
prostate cancer cells. 
 
Tumor cells maintain Perlecan under poor androgen/growth factor conditions 
The LNCaP series showed a large decrease in BrdU incorporation in response to 
Perlecan siRNA, indicating Perlecan based growth dependence under normal conditions 
regardless of their tumorigenic or metastatic potential. Our tissue microarray studies 
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Figure B-5.  Perlecan function under androgen and growth factor limitation. A. 
Minimal changes in Perlecan mRNA levels in LNCaP-derived cell lines upon serum 
starvation. RealTime PCR analysis of Perlecan mRNA levels presented as fold increase 
in Perlecan under normal (black bars) or starved (grey bars) growth conditions. While 
Perlecan mRNA is decreased in LNCaP, all other cell lines demonstrate no change in 
Perlecan mRNA levels. B. Top Panel: No change in Perlecan protein levels upon serum 
starvation. Agarose based western blots from protein extracts derived from exponentially 
growing or serum starved LNCaP, C4, C4-2, and C4-2B cells. No significant differences 
are noted in protein levels between the cell lines or under the differing conditions. 
Bottom Panel: Equivalent amounts of the same samples loaded on traditional SDS 
PAGE and probed for GAPDH as a loading control. C. Increases in expression of SHH 
and Gli-1 mRNA upon serum starvation. Real-Time PCR analysis of SHH (black bars) 
and GLI1 (grey bars) as increased fold change compared to normal growth conditions. 
Gene expression determined by All Real Time PCR with an n = 9 and normalized to 
Beta-actin. Error bars indicate standard deviation. 
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showed a correlation between Perlecan/SHH co-localization and both higher Gleason 
grade and stronger Ki-67 staining, suggesting that more aggressive or metastatic cells are 
more likely to use Perlecan-mediated SHH signaling. Since rapidly growing tumors tend 
to create microenvironments depleted of growth factors we asked if growth 
factor/androgen depletion via serum starvation would trigger the upregulation of 
Perlecan in an effort to more effectively use limiting growth factors such as SHH. In the 
parental LNCaP cell line, Perlecan mRNA levels decreased upon serum starvation 
(Figure B-5A). However, the androgen insensitive C4, C4-2 and C4-2B lines maintained 
or increased their levels Perlecan expression upon serum starvation. Immunoblotting for 
Perlecan protein confirms these results for the cell lines under normal and serum 
starvation conditions (Figure B-5B). We then asked if the expression of Perlecan in 
more metastatic lines under poor growth conditions correlated with SHH signaling 
activity. Real-Time PCR analysis for mRNA expression of SHH and the SHH response 
gene GLI1 upon starvation (Figure B-5C) demonstrated that while expression of both 
SHH and GLI1 dropped in the LNCaP cell line, expression of both genes increased in the 
more tumorigenic and metastatic cell lines. Thus the level of GLI1 expression correlates 
with changes in Perlecan expression upon serum starvation in the LNCaP series (Figure 
B-5A). This suggests that tumor cells such as C4, C4- 2 and C4-2B that are capable of 
forming tumors and/or metastasizing without stromal support maintain a high level of 
SHH signaling under adverse growth conditions by maintaining high levels of Perlecan 
and SHH expression. 
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DISCUSSION 
Perlecan, a candidate oncogene for the CAPB locus 
Using a bioinformatics based approach we identified Perlecan as a candidate 
oncogene involved in both prostate cancer and glioblastoma multiforme based on its 
genetic association with the CAPB locus at 1p36. Here we demonstrate Perlecan's 
expression and functional role in prostate cancer, and link it to the Sonic Hedgehog 
pathway known to be involved in glial tumorigenesis (Dahmane et al., 2001). Thus from 
genetic mapping, physiological, and expression data there is evidence to suggest that 
Perlecan is a strong candidate for the CAPB oncogene. The results of interference with 
Perlecan function demonstrate that this proteoglycan is required for the growth of 
prostate cancer cells, extending its previously described roles in melanoma, colon, and 
lung cancer (Cohen et al., 1994; Nackaerts et al., 1997; Sharma et al., 1998) and 
emphasizing Perlecan's role in multiple tumor types. Of note, genetic mapping studies 
have also identified a link between familial melanoma and 1p36, providing another link 
between Perlecan and tumorigenesis (Greene, 1999). 
 
Perlecan's regulation of growth factors and the link to Sonic Hedgehog 
As Perlecan has been shown to bind a variety of growth factors in different 
tumors, the question as to which growth factor is being modulated in prostate cancer 
arose. Sonic Hedgehog has been associated with brain tumors and melanomas, two 
tumors with known genetic links to 1p36, where Perlecan is located (Greene, 1999; 
Janer et al., 2003). Sonic Hedgehog has recently been linked to prostate cancer through a 
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variety of studies (Datta and Datta, 2006). We have demonstrated an increased 
frequency of Sonic Hedgehog positivity in prostate cancer tissue microarrays, and that 
Sonic Hedgehog signaling regulates tumor cell growth in both primary prostate tumor 
samples and prostate cancer cell lines (Sanchez et al., 2004). High levels of Sonic 
Hedgehog activity, as monitored by PTCH1, GLI1 or HIP expression, are present in all 
metastatic prostate cancer samples that have been tested (Karhadkar et al., 2004; Sheng 
et al., 2004). In fact, high levels of PTCH1 and HIP expression correlate with high (8–
10) Gleason scores (Sheng et al., 2004)where we have observed Perlecan expression. 
Furthermore, activation of the Sonic Hedgehog pathway by expression of Gli in the low 
metastatic potential rat AT2.1 cell line produced highly metastatic behavior, suggesting 
that high-level activation of the Sonic Hedgehog pathway determines metastatic 
behavior (Karhadkar et al., 2004). Finally, Sonic Hedgehog promotes the growth of 
LNCaP derived xenograft tumors in mice (Fan et al., 2004). We examined the potential 
of Perlecan to regulate Sonic Hedgehog signaling in tumors. The importance of heparan 
sulfate proteoglycans for Sonic Hedgehog signaling has been demonstrated in neural 
development, as mutations in the heparan sulfate binding site on Sonic Hedgehog causes 
decreased Sonic Hedgehog-driven proliferation (Rubin et al., 2002). In Drosophila, 
mutations in either Perlecan, or heparan sulfate synthesis or modification genes, greatly 
perturb Hedgehog signaling efficiency by affecting Hedgehog transport and binding 
(Bellaiche et al., 1998; Bornemann et al., 2004; Datta, 1995; Datta et al., 2006b)]. Here 
we extend these findings in development to neoplasia by demonstrating that Sonic 
Hedgehog both co-localizes and directly binds to Perlecan in tumors, and that Sonic 
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Hedgehog signaling occurs through Perlecan. This links Perlecan to the Sonic 
Hedgehog-Patched-Gli signaling pathway involved in prostate cancer (Datta and Datta, 
2006), where Perlecan acts to modulate the effects of Sonic Hedgehog. As the Sonic 
Hedgehog signaling pathway has been linked to multiple tumor types including prostate, 
stomach, brain, and skin tumors (Datta and Datta, 2006) this evidence suggests a more 
general role for Perlecan in tumor regulation and tumorigenesis. We have surveyed a 
variety of tumor types and found SHH and Perlecan colocalization in a number of these, 
such as squamous cell carcinomas and adenocarcinomas of various origins along with 
tumors deriving from areas of normal Perlecan expression such as chondrosarcomas and 
osteosarcomas (data not shown). 
 
Perlecan in familial versus sporadic prostate cancers 
We have demonstrated a positive correlation between Perlecan immunostaining 
and prostate tumors, in particular for high Gleason score tumors (Table B-1). While 
genetic mapping studies make Perlecan an excellent candidate for the CAPB oncogene, 
our clinical validation has been performed on prostate samples without information 
regarding their familial prostate cancer history. Due to the rarity of families with familial 
brain and prostate tumors, it is most likely that the tumors studied do not represent 
CAPB kindreds. The suggested role of Perlecan in up-regulating Sonic Hedgehog 
signaling in sporadic prostate tumors, combined with its association with a prostate 
cancer genetic susceptibility locus, places Perlecan among a small group of genes with 
links to both familial and sporadic prostate cancers. This dual placement implies that 
 160 
Perlecan is part of a common oncogenesis pathway that both familial and sporadic 
tumors may traverse during oncogenesis. Of note, other members of the Sonic Hedgehog 
pathway, namely SU(FU), GLI1 and SMOH also map to areas implicated in familial 
genetic studies (Datta and Datta, 2006)and are up-regulated in studies of sporadic 
prostate cancer tumors (Karhadkar et al., 2004; Sanchez et al., 2004; Sheng et al., 2004). 
Thus combining genetic analyses with evaluation of spontaneous tumors may allow us to 
identify the common pathways for carcinogenesis. 
 
Perlecan's role in prostate tumor growth: selective growth advantage for aggressive 
tumor cells under low androgen and/or growth factor conditions 
High levels of Perlecan protein correlate significantly with aggressive, highly 
proliferating prostate tumors in our tissue microarrays and are also up-regulated in 
aggressive tumors from individual patients. Yet Perlecan is not present or overexpressed 
in every tumor or even in every metastatic site of tumor spread. While this result is not 
surprising considering the heterogeneity of neoplasia, it does suggest that subsets of 
tumors may utilize Perlecan signaling in specific situations. This correlation is 
demonstrated in the varied responses of the LNCaP-derived prostate cancer cell lines 
under poor growth conditions. In these situations Perlecan expression is maintained in 
the C4, C4-2, and C4-2B cell lines capable of forming stromaindependent tumors while 
the LNCaP parental line requires stromal support to form tumors and cannot maintain 
the Perlecan specific growth advantage (Wu et al., 1994). This trait suggests a survival 
benefit to the more tumorigenic and metastatic tumor cells. Under poor growth 
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conditions where low androgen and growth factor concentrations are present, the 
increased presence of Perlecan and its ability to concentrate growth factors would 
provide a survival advantage for tumor cells until a more suitable microenvironment can 
be found. In fact, our studies show that relative up-regulation of Perlecan expression by 
the more metastatic lines during serum starvation allowed them to maintain their levels 
of SHH stimulation, while the relative down-regulation of Perlecan expression in 
LNCaP resulted in decreased SHH signaling activity. Even under normal growth 
conditions, the more metastatic cell lines were able to form more Perlecan-SHH 
complexes and obtain greater SHH stimulation. Thus in the changing tumor 
microenvironment the more metastatic tumor cells have a choice of pathways (androgen, 
Perlecan-SHH) that can be modified or modulated to maintain tumor growth. Heparan 
sulfate proteoglycans such as Perlecan have been shown to bind growth factors and may 
act as reservoirs or co-receptors for many growth factors (Wu et al., 1994). Thus 
increasing Perlecan levels under growth factor limiting conditions such as within an 
inadequately vascularized tumor would be beneficial to a tumor cell. We propose that 
Perlecan may sustain the growth of nutrient starved prostate cancer cells in rapidly 
spreading tumors by amplifying their sensitivity and response to SHH signaling. These 
findings are summarized in a model of Perlecan action (Figure B-6); in 
microenvironments with decreased growth factors and androgen, such as those 
encountered by rapidly growing tumors, Perlecan provides a secondary pathway for 
growth through SHH. This is used in both the androgen responsive and androgen 
insensitive aggressive tumor cells. Based on this model, one would hypothesize that  
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Figure B-6.  Modulation of androgen and Perlecan regulated Sonic Hedgehog 
signaling.  As changes occur to the tumor microenvironment, prostate cancer cells 
modulate their use of both androgen and Perlecan mediated Sonic Hedgehog signaling. 
The use of androgen (T) occurs via the androgen receptor (AR). Perlecan (P) is 
produced, binds Sonic Hedgehog (S) and signals through the Gli (G) proteins. The 
heaviness of each arrow indicates relative signaling strength (gene expression, complex 
formation). Androgen sensitive cells (LNCaP) utilize both androgen and Perlecan-SHH 
signaling under normal conditions, but decrease Perlecan-SHH signaling under poor 
growth conditions. In contrast aggressive androgen insensitive cells (C4, C4-2, C4-2B) 
utilize both pathways, and upregulate the Perlecan-SHH signaling under poor growth 
conditions. This may occur through increased SHH binding affinity to Perlecan. 
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chemotherapeutic treatments that simultaneously target both the androgen and the 
Perlecan-mediated Sonic Hedgehog pathways would provide the best control of 
androgen sensitive aggressive prostate cancer. 
 
Perlecan as a global regulator of growth factor action 
While we have demonstrated that Sonic Hedgehog is critical to Perlecan-
dependent cancer cell growth, other growth factors may also be regulated through 
Perlecan at different times or in different clinical stages. Recent results (Savore et al., 
2005) suggest that Perlecan may regulate the activity of different growth factors during 
metastasis to bone. Thus the true role of Perlecan may not be regulating a single growth 
factor, but its ability to allow the tumor cell to adapt to differing tumor 
microenvironments by facilitating the signaling of different growth factors. If this is 
shown to be true, Perlecan may be an excellent target for drug targeting, with tumor 
specific targeting achieved through the selective blocking of specific growth factor 
binding sites on Perlecan. 
 
Perlecan function in metastasis, a role in the bony matrix 
Perlecan is secreted by tumor cells, but is also present in specific stromal 
microenvironments in the body. This may affect a tumor's propensity to spread to 
specific sites. We have shown here that prostate cancer maintains Perlecan expression 
when it spreads to the lung or liver, but is less likely to do this in the soft tissue or lymph 
nodes. Maintaining or finding "Perlecan rich" sites may explain the propensity of tumors 
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to home to specific sites during metastatic spread. A specific example of a Perlecan rich 
site would be the bone extracellular matrix, a major site for prostate cancer metastasis. In 
these sites Perlecan plays a role in normal bone formation and regulation through the 
modulation of growth factors utilized by osteoblasts (Hassell et al., 2002; Hecht et al., 
2002; van der Horst et al., 2003). Recent studies using the bone-targeted prostate cancer 
line C4-2B show that Perlecan is required for development of metastases through the 
modulation of growth factors, and leads to efficient tumor growth and vascularization 
(Savore et al., 2005). Thus it appears that the presence of Perlecan in the bony matrix 
may help explain the tropism of prostate cancer to the bony matrix. Use of Perlecan as a 
drug target may prove advantageous by blocking bone metastasis and its associated 
morbidity. Lastly, Perlecan, as a secreted protein, may prove to be a useful biomarker for 
metastatic prostate cancer as well as a marker of either the risk or detection of tumor 
metastasis to bone since it can be easily detected in urine or serum samples, respectively. 
 
METHODS 
Bioinformatics based analysis for candidate genes in the CAPB region 
The 1p36 region, as defined by the chromosomal basepair data present in the 
human genome build 16 from the UCSC Genome Browser datasets, was searched for 
defined genes as identified in the NCBI LocusLink database. This search identified 
5,108 expressed exons comprising 659 identified transcripts and 619 defined genes. 
Using text mining we searched a dataset of 3,737 prostate cancer genes as defined by co 
localization of the gene name based on a hand annotated list from LocusLink and the 
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words "prostate cancer" in MEDLINE. From this dataset 14 genes in the 1p36 region 
had been described in prostate cancer studies. A second text-mining search we identified 
15 genes in the CAPB region that also had been described in studies of the brain. None 
of the genes in the brain or prostate cancer text mining datasets were common. We then 
focused our examination on CAPB region genes with associated data in brain studies, 
and prostate and prostate cancer expression data from the Cancer Genome Anatomy 
Project (CGAP) along with cDNA microarray expression data generated in our 
laboratory for the prostate cancer cell lines LNCaP, DU-145, and PC3. A comparison of 
these datasets revealed three genes, EPHA2, HSGP2, and CAP2B, with data in both 
brain research studies and expression in the prostate cancer or the precancerous change 
high grade prostatic intraepithelial neoplasia. Of these three genes, HSPG2 also was 
contained within our prostate cancer cell line cDNA expression datasets, with increased 
levels of expression in the derived invasive sublines of PC3 when compared to a derived 
non-invasive subline. 
 
Prostate samples and tissue culture 
LNCaP, PC3 and DU-145 cell lines were obtained from ATCC and grown under 
standard conditions. The LNCaP series LNCaP, C4, C4-2 and C4-2B were obtained 
from Dr. L. Chung. All primary prostate tumors were obtained by MWD using approved 
protocols with informed consent on the part of the subjects. 
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Real-time PCR on cell line RNA samples 
Total RNA isolated from cell lines using Trizol and then further purified using 
the RiboPure kit (Ambion). Purified RNA was digested with DNAse (Invitrogen), and 
analyzed using the SYBER Green system according to manufacturers protocols (Applied 
Biosystems) on an ABI Prism 7700 machine. Each sample was run in triplicate at three 
different concentrations. Primers were designed using Primer Express software and are 
available upon request. Fold increase/decrease comparisons were calculated using the 
delta-delta Ct method. 
 
Tissue microarray and immunohistochemistry 
Upon institutional review board approval, a tissue microarray was prepared from 
288 radical prostatectomy cases present at the Medical College of Wisconsin. A second 
tissue microarray was prepared from samples collected under approved protocols at the 
University of Pittsburgh Medical Center. 0.6 mm cores were arrayed and 5 um sections 
processed. Benign tissue, high-grade prostatic intraepithelial neoplasia, or invasive 
tumor tissue were identified by MWD or RD by high molecular weight cytokeratin 
staining (CK903 Ab, DAKO). A third tissue microarray was prepared from samples 
collected under approved protocols as part of the rapid autopsy program at the 
University of Michigan. For microarray samples, a common antigen retrieval procedure 
was carried out. Slides were processed for Perlecan or SHH and developed with HRP 
conjugated secondary antibodies and DAB substrate. For a portion of the tissue 
microarray anonymous de-identified pathologic and outcomes data were available. 
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Individual cores were examined as duplicates and staining correlated using Chi-squared, 
Fisher's Exact or two-tailed ANOVA analyses. 
 
Transfection and proliferation assays 
Purified and desalted siRNAs were purchased from Ambion as a proprietary non-
validated Perlecan siRNA and a scrambled siRNA control. SiRNA and GLI1 expression 
vector transfections were carried out with Lipofectamine 2000 (Invitrogen) as described 
by the manufacturer and effects measured after 72 hours. Casodex was used in cell 
cultures as described previously. Immunocytochemistry on cell lines was carried out 
using with anti-BrdU (Research Diagnostics or Becton-Dickinson) and HRP-conjugated 
secondary antibodies (Boehringer Mannheim) using standard techniques. 
 
Protein extracts, Western blotting and immunoprecipitations 
Normal and tumor tissue from the same patients were obtained as described 
below following approved protocols. Sections were assessed pathologically by a 
urologic pathologist (MWD) to determine areas of normal and tumor tissue. Samples 
were microdissected and total protein isolated. Proteins were also isolated from cultured 
medium from cell lines grown under normal or serum starved conditions. Proteins were 
run on a 1.6% agarose gel, blotted and probed for Perlecan (Chemicon). Equal samples 
were loaded onto a standard SDS-PAGE gel, blotted and probed for GAPDH (Santa 
Cruz) as a loading control. Equal amounts of conditioned medium from equivalently 
confluent cell lines were immunoprecipitated with an anti- Perlecan or unrelated control
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antibody, the resulting complex run on denaturing SDS-PAGE, and the presence of SHH 
verified by immunoblotting (Santa Cruz). 
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